Methods for preparing a phage library

Abstract

The present invention provides a method for producing a phage library that displays an antibody or antibody fragment, comprising: providing a first polynucleotide comprising an LC, a second polynucleotide comprising a linker, and a third polynucleotide comprising an HC; introducing the first polynucleotide, the second polynucleotide, and the third polynucleotide into a first bacterium, a second bacterium, and a third bacterium, respectively, to obtain a light chain component bacterial library, a linker component bacterial library, and a heavy chain component bacterial library; obtaining a light chain component plasmid, a linker component plasmid, and a heavy chain component plasmid from the libraries; obtaining the released LC, released linker, and released HC therefrom; ligating them to the released display vector fragment to form a ligation product for display; and introducing the resulting product into a fourth bacterium to obtain a display bacterial library; and using the display bacterial library to prepare a phage library that displays the antibody or antibody fragment. The present invention also provides a phage library produced by this method.

Description

[Technical field]

[0001] The present invention relates to the biomedical field, and in particular to a method for producing a phage library displaying antibodies or antibody fragments. [Background technology]

[0002] There are several methods for preparing phage libraries in the art, but they all have certain drawbacks. For example, the library volume of the library is too small (e.g., the volume is 10 9 In addition, the diversity of the library is insufficient, so that the screening needs for high-quality antibodies cannot be met. At the same time, in order to expand the library capacity, a large number of small libraries need to be accumulated, which not only takes several years of time, but also makes it difficult to ensure the consistency between these small libraries, so that the quality of the resulting library cannot be controlled. In addition, in the construction of libraries by conventional methods, it is difficult to conveniently and reliably perform quality control in the process of preparing the library, and the quality of the library is usually only known after it is created, so that the risk is high and the probability of failure is large.

[0003] Furthermore, libraries prepared by conventional methods are expensive, have long cycle times, and suffer from severe quality degradation during long-term storage, making them unable to meet the requirements of industrial production.

[0004] Therefore, it is necessary to prepare a large-scale phage library by a method that allows quality control to meet the requirements of industrial production and is easy to operate. Summary of the Invention

[0005] The present invention provides a method for producing a phage library displaying an antibody or antibody fragment, a phage library produced by said method, and a method for screening an antibody or antibody fragment using said phage library. The method for producing a phage library displaying an antibody or antibody fragment described in the present invention has the following features: 1) effectively reduces the probability of introducing mutations by PCR, and the phage library described in the present invention does not use a combination of PCR countermeasures used in conventional antibody library construction methods in the art, and each component for constructing the phage library is amplified once by PCR, and a phage library of Fab can be obtained by simply linking the required components; 2) can meet the requirements for industrial production; 3) can easily perform quality control, and each step required for constructing the phage library described in the present invention can be quality controlled independently and easily; and When a phage library is obtained, its quality can be easily analyzed (e.g., gene sequencing or soluble Fab expression analysis can be used); 4) the preparation process is simple and fast; the construction of the phage library described in the present invention can utilize a special restriction endonuclease recognition site, so that directed ligation is guaranteed and misligation is prevented; in the case of ligation, the molecular number of each component fragment can be controlled to 1:1, thereby improving the ligation transformation efficiency; at the same time, measures for constructing a bacterial library such as a light chain component bacterial library can be used to increase the ligation and transformation efficiency of each antibody or its fragment (e.g., the obtained ligation product has a transformation efficiency of about 10 per μg). 9), by obtaining a linker component plasmid, it is ensured that the released linker obtained has a suitable and complete sticky end, and the efficiency of ligation transformation is increased, and the phage library described in the present invention may be cultured in a dish or in liquid, 5) the library produced is large in volume and has good diversity, which contributes to rapid and effective screening of antibodies or antigen-binding fragments thereof, 6) high specificity, the construction of the phage library described in the present invention does not utilize degenerate primers used in conventional methods in the art, thereby avoiding errors caused by the degenerate primers, and the primers for constructing the phage library described in the present invention require high PCR annealing temperatures, which can increase the binding specificity between the primers and their amplified target fragments, and 7) amplifiable and easy to store, and the bacterial library, such as the light chain component bacterial library, and the bacteria containing the linker component plasmid can both be stored for a long period of time under -80°C conditions and can be taken out at any time when used (for example, the phage library described in the present invention can be obtained in just two days), and can be mixed in different types and ratios as needed.

[0006] On the other hand, the present invention provides a method for producing a phage library displaying an antibody or antibody fragment, comprising: 1) providing a first polynucleotide comprising an LC having a nucleic acid sequence encoding a light chain or light chain fragment of said antibody or antibody fragment, a second polynucleotide comprising a linker, and a third polynucleotide comprising an HC having a nucleic acid sequence encoding a heavy chain or heavy chain fragment of said antibody or antibody fragment; 2) obtaining a light chain component bacterial library by introducing said first polynucleotide into a first bacterium, obtaining a linker component bacterium by introducing said second polynucleotide into a second bacterium, and obtaining a heavy chain component bacterial library by introducing said third polynucleotide into a third bacterium; 3) obtaining a light chain component plasmid comprising said LC from said light chain component bacterial library, and obtaining a linker component plasmid comprising said linker from said linker component bacterium; and obtaining a heavy chain component plasmid comprising the HC from the heavy chain component bacterial library; 4) obtaining the LC released from the light chain component plasmid, obtaining the linker released from the linker component plasmid, and obtaining the HC released from the heavy chain component plasmid; 5) providing a display vector, and obtaining a display vector fragment released from the display vector; 6) ligating the released LC, released linker, released HC, and released display vector fragment to form a ligation product for display; 7) introducing the ligation product for display into a fourth bacterium to obtain a display bacterial library of the antibody or antibody fragment; and 8) using the display bacterial library to prepare a phage library displaying the antibody or antibody fragment.

[0007] In some embodiments, under conditions suitable for expression of the antibody or antibody fragment, the ligated product for display in 6) can express the light chain or light chain fragment and the heavy chain or heavy chain fragment in accordance with the reading frame.

[0008] In some embodiments, the first polynucleotide, the second polynucleotide, and the third polynucleotide are all linear nucleic acid molecules.

[0009] In some embodiments, the nucleic acid sequence encoding the heavy chain or heavy chain fragment and the nucleic acid sequence encoding the light chain or light chain fragment are located in different reading frames.

[0010] In some embodiments, the linker comprises a nucleic acid sequence encoding the signal peptide pelB or a fragment thereof, In some embodiments, the linker is about 50 to about 200 bases in length.

[0011] In some embodiments, in the ligation product for display in 6), the LC is upstream of the linker, and the linker is upstream of the HC.

[0012] In some embodiments, 2) comprises cryopreserving said light chain component bacterial library and / or said heavy chain component bacterial library.

[0013] In some embodiments, 7) comprises cryopreserving the display bacterial library.

[0014] In some embodiments, 8) includes thawing and culturing the cryopreserved display bacterial library, and constructing the phage library with the cultured display bacterial library.

[0015] In some embodiments, the first polynucleotide comprises, in a 5'→3' direction, the structure R1-LC-R2, the second polynucleotide comprises, in a 5'→3' direction, the structure R3-Linker-R4, the third polynucleotide comprises, in a 5'→3' direction, the structure R5-HC-R6, and the display vector comprises, in a 5'→3' direction, the structure R7-Display Vector Fragment-R8, wherein R1, R2, R3, R4, R5, R6, R7 and R8 are recognition sites for a restriction endonuclease.

[0016] In some embodiments, the end cleaved by the restriction endonuclease of R2 can recognize and link to the end cleaved by the restriction endonuclease of R3, and does not recognize or link to the end cleaved by any of the restriction endonucleases of R1, R4, R5, R6, R7 and R8.

[0017] In some embodiments, the end cleaved by the restriction endonuclease R4 can recognize and link to the end cleaved by the restriction endonuclease R5, and does not recognize or link to the end cleaved by any of the restriction endonucleases R1, R2, R3, R6, R7, and R8.

[0018] In some embodiments, the end cleaved by the restriction endonuclease R6 can recognize and link to the end cleaved by the restriction endonuclease R7, and does not recognize or link to the end cleaved by any of the restriction endonucleases R1, R2, R3, R4, R5 and R8.

[0019] In some embodiments, the end cleaved by the restriction endonuclease of R8 can recognize and link to the end cleaved by the restriction endonuclease of R1, and does not recognize or link to the end cleaved by any of the restriction endonucleases of R2, R3, R4, R5, R6 and R7.

[0020] In some embodiments, the ends cleaved by the restriction endonuclease of any of R1, R2, R3, R4, R5, R6, R7 and R8 above are non-palindromic sequences.

[0021] In some embodiments, two or more of R1, R2, R3, R4, R5, R6, R7 and R8 are recognizable and cleavable by the same restriction endonuclease.

[0022] In some embodiments, R2 is the same as R3. In some embodiments, R4 is the same as R5. In some embodiments, R6 is the same as R7. In some embodiments, R8 is the same as R1.

[0023] In some embodiments, R1, R2, R3, R4, R5 and R8 are recognizable and cleavable by the same restriction endonuclease. In some embodiments, R6 and R7 are recognizable and cleavable by the same restriction endonuclease.

[0024] In some embodiments, the restriction endonuclease is selected from SfiI, BsmBI and Esp3I. In some embodiments, R1, R2, R3, R4, R5 and R8 are recognizable and cleavable by SfiI. In some embodiments, R6 and R7 are recognizable and cleavable by BsmBI and / or Esp3I.

[0025] In some embodiments, R1 has the nucleic acid sequence represented by SEQ ID NO:1.

[0026] In some embodiments, R2 has the nucleic acid sequence represented by SEQ ID NO:2.

[0027] In some embodiments, R3 has a nucleic acid sequence represented by SEQ ID NO:2.

[0028] In some embodiments, R4 has the nucleic acid sequence represented by SEQ ID NO:3.

[0029] In some embodiments, R5 has the nucleic acid sequence represented by SEQ ID NO:3.

[0030] In some embodiments, R6 has the nucleic acid sequence represented by SEQ ID NO:4.

[0031] In some embodiments, R7 has the nucleic acid sequence represented by SEQ ID NO:4.

[0032] In some embodiments, R8 has the nucleic acid sequence represented by SEQ ID NO:1.

[0033] In some embodiments, the light chain or light chain fragment comprises a light chain variable region portion and / or a light chain constant region portion. In some embodiments, the heavy chain or heavy chain fragment comprises a heavy chain variable region portion and / or a heavy chain constant region portion. In some embodiments, the antibody or fragment thereof comprises Fab, Fab', (Fab)2 and / or (Fab')2.

[0034] In some embodiments, the ligation product for display in 7) has a ligation transformation efficiency of at least 10 8 clones / μg polynucleotide.

[0035] In some embodiments, 2) comprises enzymatically digesting the first polynucleotide with a restriction endonuclease that recognizes R1 and R2 to obtain the light chain storage vector fragment by ligating the enzymatically digested first polynucleotide to a light chain storage vector fragment to form a light chain storage ligation product, and introducing the product into the first bacterium to obtain the light chain component bacterial library, wherein the light chain storage vector comprises R1 and R2, and wherein the light chain storage vector is enzymatically digested with a restriction endonuclease that recognizes R1 and R2 to obtain the light chain storage vector fragment.

[0036] In some embodiments, the light chain storage vector is derived from a pUC vector. In some embodiments, the pUC vector is a pUC19 vector or is derived from a pUC19 vector. In some embodiments, the pUC vector is a pMD19-T vector or is derived from a pMD19-T vector.

[0037] In some embodiments, the restriction endonuclease that recognizes R1 and R2 comprises SfiI.

[0038] In some embodiments, 2) includes enzymatically digesting the third polynucleotide with a restriction endonuclease that recognizes R5 and R6, ligating the enzymatically digested third polynucleotide to a heavy chain storage vector fragment to form a heavy chain storage ligation product, and introducing the product into the third bacterium to obtain the heavy chain component bacterial library, where the heavy chain storage vector includes R5 and R6, and enzymatically digesting the heavy chain storage vector with a restriction endonuclease that recognizes R5 and R6 to obtain the heavy chain storage vector fragment. In some embodiments, the heavy chain storage vector is derived from a pUC vector. In some embodiments, the pUC vector is a pUC19 vector or is derived from a pUC19 vector. In some embodiments, the pUC vector is a pMD19-T vector or is derived from a pMD19-T vector.

[0039] In some embodiments, the heavy chain conservation vector contains a recognition site for BsmBI, and contains one.

[0040] In some embodiments, the restriction endonucleases that recognize R5 and R6 include SfiI, BsmBI and / or Esp3I.

[0041] In some embodiments, 2) comprises ligating the second polynucleotide to a vector fragment to form a linker-storing vector, and introducing the linker-storing vector into the second bacterium, thereby obtaining the linker component bacterium. In some embodiments, the linker-storing vector comprises R3 and R4. In some embodiments, the vector fragment for constructing the linker-storing vector is derived from a pUC vector. In some embodiments, the pUC vector is a pUC19 vector or is derived from a pUC19 vector. In some embodiments, the pUC vector is a pMD19-T vector or is derived from a pMD19-T vector.

[0042] In some embodiments, 4) comprises obtaining the released LC by enzymatic digestion of the light chain component plasmid with a restriction endonuclease that recognizes R1 and R2. In some embodiments, the restriction endonuclease that recognizes R1 and R2 comprises SfiI.

[0043] In some embodiments, 4) comprises obtaining the released HC by enzymatic digestion of the heavy chain component plasmid with a restriction endonuclease that recognizes R5 and R6. In some embodiments, the restriction endonuclease that recognizes R5 and R6 comprises SfiI, BsmBI and / or Esp3I.

[0044] In some embodiments, 4) includes obtaining the released linker by performing an enzymatic digestion treatment on the linker-storing vector using a restriction endonuclease that recognizes R3 and R4. In some embodiments, 4) includes obtaining an amplification product including the linker, R3, and R4 from the linker-storing vector, and obtaining the released linker by performing an enzymatic digestion treatment on the amplification product using a restriction endonuclease that recognizes R3 and R4. In some embodiments, the restriction endonuclease that recognizes R3 and R4 includes SfiI.

[0045] In some embodiments, 5) comprises performing an enzymatic digestion of the display vector with a restriction endonuclease that recognizes R7 and R8 to release the display vector fragment. In some embodiments, the restriction endonuclease that recognizes R7 and R8 comprises SfiI, BsmBI, and / or Esp3I.

[0046] In some embodiments, the display vector is derived from the pComb3x vector.

[0047] In some embodiments, when the display vector is subjected to enzymatic digestion using restriction endonucleases that recognize R1, R2, R3, R4, R5, and R8, three different enzymatic digestion fragments are obtained. In some embodiments, the restriction endonucleases that recognize R1, R2, R3, R4, R5, and R8 include SfiI. In some embodiments, when the display vector is subjected to enzymatic digestion using restriction endonucleases that recognize R6 and R7, the display vector is linearized. In some embodiments, the restriction endonucleases that recognize R6 and R7 include BsmBI and / or Esp3I.

[0048] In some embodiments, when the display vector is subjected to enzymatic digestion using restriction endonucleases that recognize R1, R2, R3, R4, R5, R6, R7, and R8, four different enzymatic digestion fragments are obtained. In some embodiments, the restriction endonucleases that recognize R1, R2, R3, R4, R5, R6, R7, and R8 include SfiI, BsmBI, and / or Esp3I.

[0049] In some embodiments, 2) comprises determining library volume and / or quality of said light chain component bacterial library, said linker component bacterial library and / or said heavy chain component bacterial library by sampling and detecting said light chain component bacterial library, said linker component bacterial library and / or said heavy chain component bacterial library.

[0050] In some embodiments, the light chain component bacterial library comprises at least 10 6 It contains different clones.

[0051] In some embodiments, the heavy chain component bacterial library comprises at least 10 7 It contains different clones.

[0052] In some embodiments, the efficient cloning rate in the light chain component bacterial library is at least about 70%.

[0053] In some embodiments, the efficient cloning rate in the heavy chain component bacterial library is at least about 70%.

[0054] In some embodiments, 2) comprises determining the volume and / or quality of the display bacterial library based on the volume, linker component volume and / or quality of the light chain component bacterial library and / or the heavy chain component bacterial library.

[0055] In some embodiments, the display bacterial library comprises at least 10 10 It contains different clones.

[0056] In some embodiments, the efficient cloning rate in the display bacterial library is at least about 70%.

[0057] In some embodiments, the first polynucleotide and the third polynucleotide are obtained from a sample of material. In some embodiments, the sample of material comprises material from a peripheral blood lymphocyte sample. In some embodiments, the peripheral blood lymphocytes are human peripheral blood lymphocytes. In some embodiments, the sample of material comprises total RNA and / or mRNA from the sample.

[0058] In some embodiments, 8) comprises preparing the phage library by contacting the display bacterial library with a helper phage.

[0059] On the other hand, the present invention provides a phage library produced by the above method. In some embodiments, the phage library comprises at least 10 10 In some embodiments, the phage library comprises at least 10 10 Different types of antibodies or antibody fragments can be displayed.

[0060] On the other hand, the present invention provides a method for screening an antibody or an antibody fragment, which comprises using the above-mentioned phage library.

[0061] Those skilled in the art will be able to easily grasp other aspects and advantages of the present disclosure from the following detailed description. In the following detailed description, only exemplary embodiments of the present disclosure are depicted and described. For those skilled in the art, the details of the present disclosure may be modified without departing from the spirit and scope of the present invention. Accordingly, in the present invention, the drawings and the description are merely examples and are not intended to limit the present invention. [Brief description of the drawings]

[0062] Specific features of the present invention are set forth in the appended claims. The features and advantages of the present invention will be more clearly understood with reference to the following detailed description of exemplary embodiments and drawings, which are generally described as follows:

[0063] FIG. 1 shows a schematic diagram of the pUC19 vector. FIG. 2 shows a schematic diagram of the modified pUC19 vector of the present invention. FIG. 3 shows a schematic diagram of the light chain storage vector according to the invention. FIG. 4 shows a schematic diagram of a linker-conserving vector according to the present invention. FIG. 5 shows a schematic diagram of the heavy chain storage vector according to the present invention. FIG. 6 shows a schematic diagram of the pCom3x vector. FIG. 7 shows a schematic diagram of a display vector according to the present invention. FIG. 8 shows a schematic diagram of a plasmid containing the ligation product for display of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0064] Hereinafter, the embodiments of the present invention will be described with reference to certain specific examples, but those skilled in the art can easily grasp other advantages and effects of the present invention from the contents disclosed in this specification.

[0065] In the present invention, the term "phage library" generally refers to a library containing polynucleotides encoding different recombinant polypeptides that can be displayed on a phage. In some cases, the phage library may further include a collection of phages that are transfected with a polynucleotide library. In the present invention, the library may be a diverse collection or mixture of polynucleotides that may include polynucleotides encoding different recombinant polypeptides. For example, the polynucleotide library collection may include at least 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 Or more different types of polynucleotides may be included. The polynucleotides in the phage library may be from a single species (e.g., a mammal, e.g., human), tissues, organs and / or cells thereof. The library may include polynucleotides of a common genus. For example, the genus may be polynucleotides that encode a particular type or class of immunoglobulin subunit polypeptide. For example, the polynucleotides may encode an antibody light chain or a light chain fragment. For example, the polynucleotides may encode an antibody heavy chain or a heavy chain fragment.

[0066] In the present invention, the term "antibody" generally refers to a polypeptide molecule capable of specifically recognizing and / or neutralizing a particular antigen. A typical four-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light chains and two identical heavy chains. In the case of IgG, each L chain is linked to the H chain by one total disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bonds. Each H chain has a variable domain (VH) at its N-terminus followed by three (for each α and γ chain) or four (for μ and ε isotypes) constant domains (CH).

[0067] In the present invention, the term "antibody fragment" generally refers to a portion of a full-length antibody. For example, the antibody fragment may contain the antigen-binding region and / or the antibody variable region of the full-length antibody. The antibody fragment may be obtained by chemical and / or genetic engineering methods. For example, the antibody fragment may be produced after digesting the antibody using proteases, including pepsin and papain. In the present invention, the antibody fragment may be a Fab.

[0068] In the present invention, the term "Fab" generally refers to the production of two identical antigen-binding fragments after digestion of an intact antibody with papain (e.g., the Fc region and hinge region have been removed). An Fab may consist of a full-length light chain, a heavy chain variable region (VH) and the first constant domain (CH1) of the heavy chain. Each Fab may have a single antigen-binding site.

[0069] In the present invention, the term "linker" generally refers to a reagent capable of linking two or more types of polynucleotide molecules or fragments thereof. The linker may be a polynucleotide or a fragment thereof. In the present invention, the linker may have different lengths. For example, the length of the linker may be 40bp or more, 50bp or more, 60bp or more, 70bp or more, 80bp or more, 90bp or more, 100bp or more, 150bp or more, 200bp or more or more.

[0070] In the present invention, the term "LC" generally refers to a polynucleotide having a nucleic acid sequence encoding a light chain or a light chain fragment of an antibody or an antibody fragment. In the present invention, the light chain or the light chain fragment can have the ability to bind to the heavy chain of the same or similar antibody. In the present invention, the light chain or the light chain fragment can include a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region can be divided into a kappa type and a lambda type. The light chain also includes a light chain of a lambda variable region (V-λ) linked to a kappa constant region (C-κ) or a kappa variable region (V-κ) linked to a lambda constant region (C-λ). For example, the LC can be a polynucleotide having a nucleic acid sequence encoding a light chain of an antibody or an antibody fragment.

[0071] In the present invention, the term "HC" generally refers to a polynucleotide having a nucleic acid sequence encoding a heavy chain or a heavy chain fragment of an antibody or antibody fragment. In the present invention, the heavy chain or heavy chain fragment can have the ability to bind to the light chain of the same or similar antibody. In the present invention, the heavy chain or heavy chain fragment can include a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region can include a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain. In the case of IgE, IgM, and IgY, the heavy chain constant region can include a CH4 domain but does not include a hinge region. In the present invention, the "heavy chain constant region" can be a CH1, a hinge region, a CH2, a CH3, a CH4 domain, or any combination thereof. For example, the HC can be a polynucleotide having a nucleic acid sequence encoding the VH and CH1 of an antibody or antibody fragment.

[0072] In the present invention, the term "first polynucleotide" generally refers to a polynucleotide comprising an LC that may have a nucleic acid sequence encoding the light chain or light chain fragment of the antibody or antibody fragment. In the present invention, the first polynucleotide may also have an endonuclease (e.g., a restriction endonuclease) recognition site at the 5'-end and / or 3'-end. For example, the first polynucleotide may comprise a structure R1-LC-R2 in the 5'->3' direction, where R1 and R2 may be restriction endonuclease recognition sites. For example, after enzymatic digestion with an endonuclease that recognizes the endonuclease recognition site in the first polynucleotide (e.g., a restriction endonuclease that recognizes R1 and R2, e.g., SfiI), the enzymatically digested first polynucleotide may comprise the LC.

[0073] In the present invention, the term "light chain preservation vector fragment" generally refers to a fragment of a light chain preservation vector enzymatically digested with a restriction endonuclease. In the present invention, the recognition site of the restriction endonuclease contained in the light chain preservation vector may correspond to and be the same as the recognition site of the restriction endonuclease contained in the first polynucleotide. For example, the light chain preservation vector may include the R1 and the R2. In the present invention, the light chain preservation vector fragment obtained can be linked to the first polynucleotide enzymatically digested after enzymatic digestion with a restriction endonuclease (for example, a restriction endonuclease that recognizes the R1 and the R2). In the present invention, the light chain preservation vector fragment may be derived from a pUC vector. For example, the pUC vector may be a pUC19 vector or may be derived from a pUC19 vector, and for example, the pUC vector may be a pMD19-T vector or may be derived from a pMD19-T vector.

[0074] In the present invention, the term "light chain conservation ligation product" generally refers to the product formed by ligating the first polynucleotide to the light chain conservation vector fragment after enzymatic digestion. In the present invention, the first polynucleotide and the light chain conservation vector fragment may contain the same restriction endonuclease recognition site, and are ligated by a ligase (e.g., DNA ligase) to obtain the light chain conservation ligation product.

[0075] In the present invention, the term "first bacterium" generally refers to a bacterium for introducing or containing the first polynucleotide. The first bacterium may contain the LC. In the present invention, the first bacterium may be introduced with the light chain conservation ligation product. In the present invention, the first bacterium can express, replicate and / or store (e.g., cryopreservation) the LC, the first polynucleotide and / or the light chain conservation ligation product.

[0076] In the present invention, the term "light chain component bacterial library" generally refers to a bacterial library obtained by introducing the first polynucleotide into the first bacterium. In the present invention, the light chain component bacterial library may be a bacterial library having nucleic acid sequences encoding light chains or light chain fragments of antibodies or antibody fragments. In the present invention, the light chain component bacterial library may be a bacterial library having nucleic acid sequences encoding light chains or light chain fragments of antibodies or antibody fragments. 5 ~about 10 9 (e.g., about 10 5 ~about 10 8 pieces, about 10 5 ~about 10 7 pieces, about 10 6 ~about 10 7 In the present invention, the light chain component bacterial library may have nucleic acid sequences encoding different light chains or light chain fragments of antibodies or antibody fragments of about 10 7 ~about 10 12 (e.g., about 10 7 ~about 10 11 pieces, about 10 7 ~about 10 10 pieces, about 10 7 ~about 10 9 pieces, about 10 7 ~about 10 8 The first bacterium may comprise at least one of the above-mentioned first bacteria.

[0077] In the present invention, the term "second polynucleotide" generally refers to a polynucleotide containing a linker. In the present invention, the second polynucleotide may also have an endonuclease (e.g., a restriction endonuclease) recognition site at the 5' end and / or 3' end. For example, the first polynucleotide may have a structure R3-linker-R4 in the 5'→3' direction, where R3 and R4 may be restriction endonuclease recognition sites. For example, after enzymatic digestion with an endonuclease that recognizes the endonuclease recognition site in the second polynucleotide (e.g., a restriction endonuclease that recognizes R3 and R4, such as SfiI), the enzymatically digested second polynucleotide may contain the linker.

[0078] In the present invention, the term "vector fragment", when used in common with a second polynucleotide or a linker, generally refers to a vector fragment that can be linked to the second polynucleotide. In the present invention, the vector fragment may be derived from a pUC vector. For example, the pUC vector may be a pUC19 vector or may be derived from a pUC19 vector, or for example, the pUC vector may be a pMD19-T vector or may be derived from a pMD19-T vector.

[0079] In the present invention, the term "linker-conserved vector" generally refers to a product formed by linking the second polynucleotide to the vector fragment. In the present invention, the restriction endonuclease recognition site contained in the linker-conserved vector may be the same as the restriction endonuclease recognition site contained in the first polynucleotide. For example, the linker-conserved vector may include R3 and R4. In the present invention, the linker-conserved vector may include only one type of linker.

[0080] In the present invention, the term "second bacterium" generally refers to a bacterium for introducing or containing the second polynucleotide. The second bacterium may contain the linker. In the present invention, the second bacterium may be introduced with the linker-storing vector. In the present invention, the second bacterium can express, replicate and / or store (e.g., cryopreservation) the linker and / or the second polynucleotide.

[0081] In the present invention, the term "linker component bacterium" generally refers to a bacterium obtained by introducing the linker-storing vector into the second bacterium. In the present invention, the linker component bacterium may be a single species of bacterium. In the present invention, the linker component bacterium of a single species may only contain a single species of the linker.

[0082] In the present invention, the term "third polynucleotide" generally refers to a polynucleotide containing an HC that may have a nucleic acid sequence encoding the heavy chain or heavy chain fragment of the antibody or antibody fragment. In the present invention, the third polynucleotide may also have a recognition site for an endonuclease (e.g., a restriction endonuclease) at the 5' end and / or 3' end. For example, the first polynucleotide may have a structure R5-HC-R6 in the 5'→3' direction, where R5 and R6 may be recognition sites for a restriction endonuclease. For example, after enzymatic digestion with an endonuclease that recognizes the endonuclease recognition site in the third polynucleotide (e.g., a restriction endonuclease that recognizes R5, such as SfiI, or a restriction endonuclease that recognizes R6, such as SfiI, BsmBI, and Esp3I), the enzymatically digested third polynucleotide may contain the HC.

[0083] In the present invention, the term "heavy chain-preserving vector fragment" generally refers to a fragment of a heavy chain-preserving vector enzymatically digested with a restriction endonuclease. In the present invention, the recognition site of the restriction endonuclease contained in the heavy chain-preserving vector may correspond to and be the same as the recognition site of the restriction endonuclease contained in the third polynucleotide. For example, the heavy chain-preserving vector may include the R5 and the R6. In the present invention, the obtained heavy chain-preserving vector fragment can be linked to the third polynucleotide enzymatically digested after enzymatic digestion with a restriction endonuclease (for example, a restriction endonuclease that recognizes the R5 and the R6). In the present invention, the heavy chain-preserving vector fragment may be derived from a pUC vector. For example, the pUC vector may be a pUC19 vector or may be derived from a pUC19 vector, or for example, the pUC vector may be a pMD19-T vector or may be derived from a pMD19-T vector.

[0084] In the present invention, the term "heavy chain preservation ligation product" generally refers to a product formed by ligating the above-mentioned third polynucleotide to the above-mentioned heavy chain preservation vector fragment after enzymatic digestion. In the present invention, the above-mentioned third polynucleotide and the above-mentioned heavy chain preservation vector fragment may contain the same restriction endonuclease recognition site, and are ligated by a ligase (e.g., DNA ligase) to obtain the above-mentioned heavy chain preservation ligation product.

[0085] In the present invention, the term "third bacterium" generally refers to a bacterium for introducing or containing the third polynucleotide. The third bacterium may contain the HC. In the present invention, the third bacterium may be introduced with the heavy chain conservation ligation product. In the present invention, the third bacterium can express, replicate and / or store (e.g., cryopreservation) the HC, the third polynucleotide and / or the heavy chain conservation ligation product.

[0086] In the present invention, the term "heavy chain component bacterial library" generally refers to a bacterial library obtained by introducing the third polynucleotide into the third bacterium. In the present invention, the heavy chain component bacterial library may be a bacterial library having nucleic acid sequences encoding heavy chains or heavy chain fragments of antibodies or antibody fragments. In the present invention, the heavy chain component bacterial library may be a bacterial library having nucleic acid sequences encoding heavy chains or heavy chain fragments of antibodies or antibody fragments. 5 ~about 10 9 (e.g., about 10 5 ~about 10 8 pieces, about 10 5 ~about 10 7 pieces, about 10 6 ~about 10 7 In the present invention, the heavy chain component bacterial library may have nucleic acid sequences encoding different heavy chains or heavy chain fragments of antibodies or antibody fragments of about 10 7 ~about 10 12 (e.g., about 10 7 ~about 10 11 pieces, about 10 7 ~about 10 10 pieces, about 10 7~about 10 9 pieces, about 10 7 ~about 10 8 The third bacterium may be present in an amount of 100 to 2000 μg / ml.

[0087] In the present invention, the term "light chain component plasmid" generally refers to a plasmid comprising the LC described above, obtained from the bacteria of the light chain component bacterial library described above. In the present invention, the light chain component plasmid may comprise the LC described above. For example, the light chain component plasmid may comprise the first polynucleotide described above. In the present invention, the light chain component plasmid may comprise restriction endonuclease recognition sites, e.g., R1 and R2.

[0088] In the present invention, the term "heavy chain component plasmid" generally refers to a plasmid obtained from a bacterium of the heavy chain component bacterial library and comprising the HC. In the present invention, the heavy chain component plasmid may comprise the HC. For example, the heavy chain component plasmid may comprise the third polynucleotide. In the present invention, the heavy chain component plasmid may comprise restriction endonuclease recognition sites, for example R5 and R6.

[0089] In the present invention, the term "released LC" generally refers to the LC released after treating the light chain component plasmid. In the present invention, the treatment can be an enzyme digestion treatment. For example, a suitable restriction endonuclease (e.g., a restriction endonuclease that recognizes R1 and R2) can be selected for the restriction endonuclease recognition sites in the light chain component plasmid to release and separate the LC from the light chain component plasmid.

[0090] In the present invention, the term "released linker" generally refers to the linker released after treating the linker component plasmid. In the present invention, the treatment can be an enzyme digestion treatment. For example, a suitable restriction endonuclease (e.g., a restriction endonuclease that recognizes R3 and R4) can be selected for the restriction endonuclease recognition site in the linker component plasmid, and the linker can be released and separated from the linker component plasmid. Also, for example, first, amplification (e.g., PCR amplification) is performed using the linker component plasmid as a template and including the second polynucleotide, and then the obtained amplification product is subjected to an enzyme digestion treatment. For example, a suitable restriction endonuclease (e.g., a restriction endonuclease that recognizes R3 and R4) can be selected for the restriction endonuclease recognition site in the linker component plasmid, and the linker can be released and separated from the linker component plasmid.

[0091] In the present invention, the term "released HC" generally refers to the HC released after treating the heavy chain component plasmid. In the present invention, the treatment can be an enzyme digestion treatment. For example, a suitable restriction endonuclease (e.g., R5 and R6) can be selected for the recognition site of the restriction endonuclease in the heavy chain component plasmid to release and separate the HC from the heavy chain component plasmid.

[0092] In the present invention, the term "released display vector fragment" generally refers to a fragment of a display vector released after processing the display vector. In the present invention, the display vector comprises the structure R7-display vector fragment-R8 in the 5'→3' direction, where R7 and R8 can be restriction endonucleases. In the present invention, the processing can be an enzymatic digestion treatment with a restriction endonuclease. For example, a suitable restriction endonuclease (e.g., R7 and R8) can be selected for the recognition site of the restriction endonuclease in the display vector, and the released display vector fragment can be released and separated from the display vector.

[0093] In the present invention, the term "ligation" generally refers to joining two or more polynucleotide molecules together. For example, the ligation may be by a ligase (e.g., DNA ligase). For example, the 3' end of one polynucleotide is ligated to the 5' end of another polynucleotide to form one full-length polynucleotide molecule.

[0094] In the present invention, the term "display ligation product" generally refers to one polynucleotide molecule containing the released LC, the released linker, the released HC and the released display vector fragment. In the present invention, the display ligation product is obtained by mixing the released LC, the released linker, the released HC and the released display vector fragment in proportion.

[0095] In the present invention, the above-mentioned "display" refers to expressing a protein (e.g., an antibody or an antibody fragment, e.g., Fab) encoded by the above-mentioned ligation product for display in a cell containing the above-mentioned ligation product for display.

[0096] In the present invention, the term "introduction" generally refers to the process of carrying or introducing an exogenous polynucleotide into a cell. The cell may be a host cell. The introduced cell includes the primary cell of interest and its progeny. The cell may be a prokaryotic cell, such as a bacterial cell.

[0097] In the present invention, the term "fourth bacterium" generally refers to a bacterium for introducing or containing the ligation product for display, which includes the released LC, the released linker, the released HC and the released display vector fragment. In the present invention, the ligation product for display can be introduced into the fourth bacterium by transformation. In the present invention, the fourth bacterium can express the light chain or light chain fragment of the antibody or antibody fragment encoded by the released LC, and can express the heavy chain or heavy chain fragment of the antibody or antibody fragment encoded by the released HC. In the present invention, the fourth bacterium can express, replicate and / or store (e.g., cryopreserv) the antibody or antibody fragment.

[0098] In the present invention, the term "display bacterial library" generally refers to a bacterial library containing the above-mentioned ligation product for display. In the present invention, the above-mentioned display bacterial library may include the above-mentioned fourth bacterium. In the present invention, the above-mentioned display bacterial library may include 10 10 The antibody may comprise one or more different antibodies or antibody fragments.

[0099] In the present invention, the term "signal peptide pelB" generally refers to the signal peptide of pectin lyase. Said signal peptide pelB is generally used in prokaryotic expression systems. For example, said signal peptide pelB may have the GenBank accession number ABS75961.1.

[0100] In the present invention, the term "restriction endonuclease" generally refers to an enzyme that cleaves double-stranded DNA. The restriction endonuclease can attach to DNA ligase by producing sticky ends containing protruding single-stranded DNA. In the present invention, the restriction endonuclease can serve as recognition and restriction cleavage. For example, the cleavage site of the restriction endonuclease is a certain distance away from its recognition site. For example, the restriction endonuclease can be selected from SfiI, BsmBI and Esp3I.

[0101] In the present invention, the term "linearization" generally refers to a circular vector that is not closed and is linear. For example, when the above vector is subjected to an enzyme digestion treatment, the original circular structure of the above vector is broken to form a linearized vector. For example, the above vector (e.g., T vector) produces one T end at the 3' end after enzyme digestion with a restriction endonuclease, and at this time, for a PCR product containing an A end, the PCR product can be directly ligated to the linear vector by the action of T4 ligase.

[0102] In the present invention, the term "clones" generally refers to the number of bacterial colonies. For example, the clones may be the number of bacterial colonies in a bacterial library (e.g., the light chain component bacterial library, the heavy chain component bacterial library, the display bacterial library, and / or the phage library). In some cases, the clones may be the number of different bacterial colonies in the bacterial library. In some cases, the clones may be the number of progeny populations produced by a single clone.

[0103] In the present invention, the term "polynucleotide" generally refers to a nucleotide, i.e., at least two nucleotides linked together. The polynucleotide may be any length polymer, for example, having 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, 100,000, etc. The polynucleotide may have phosphodiester bonds.

[0104] In the present invention, the term "comprising" generally refers to specifically specified features but does not exclude other elements.

[0105] In the present invention, the term "about" generally refers to a range of 0.5% to 10% more or less than the specified number, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% more or less than the specified number.

[0106] On the other hand, the present invention provides a method for producing a phage library displaying an antibody or antibody fragment, comprising: 1) providing a first polynucleotide comprising an LC having a nucleic acid sequence encoding a light chain or light chain fragment of said antibody or antibody fragment, a second polynucleotide comprising a linker, and a third polynucleotide comprising an HC having a nucleic acid sequence encoding a heavy chain or heavy chain fragment of said antibody or antibody fragment; 2) obtaining a light chain component bacterial library by introducing said first polynucleotide into a first bacterium, obtaining a linker component bacterium by introducing said second polynucleotide into a second bacterium, and obtaining a heavy chain component bacterial library by introducing said third polynucleotide into a third bacterium; 3) obtaining a light chain component plasmid comprising said LC from said light chain component bacterial library, and obtaining a linker component plasmid comprising said linker from said linker component bacterium; and obtaining a heavy chain component plasmid comprising the HC from the heavy chain component bacterial library; 4) obtaining the LC released from the light chain component plasmid, obtaining the linker released from the linker component plasmid, and obtaining the HC released from the heavy chain component plasmid; 5) providing a display vector, and obtaining a display vector fragment released from the display vector; 6) ligating the released LC, released linker, released HC, and released display vector fragment to form a ligation product for display; 7) introducing the ligation product for display into a fourth bacterium to obtain a display bacterial library of the antibody or antibody fragment; and 8) using the display bacterial library to prepare a phage library displaying the antibody or antibody fragment.

[0107] In the present invention, under conditions suitable for expression of an antibody or antibody fragment, the ligation product for display in 6) can express the light chain or light chain fragment and the heavy chain or heavy chain fragment according to the reading frame.

[0108] In the present invention, the first polynucleotide, the second polynucleotide, and the third polynucleotide may all be linear nucleic acid molecules.

[0109] In the present invention, the nucleic acid sequence encoding the heavy chain or heavy chain fragment and the nucleic acid sequence encoding the light chain or light chain fragment may be located in different reading frames. In the present invention, the reading frame may be a continuous nucleotide sequence from the start codon to the stop codon, the inside of which does not contain any promoter or terminator. For example, the reading frame may encode a protein or polypeptide fragment.

[0110] In the present invention, said linker may comprise a nucleic acid sequence encoding the signal peptide pelB or a fragment thereof.

[0111] In the present invention, the linker may have a nucleic acid sequence encoding a fragment of signal peptide pelB, and the remaining nucleic acid sequence encoding the fragment of signal peptide pelB may also be located in R5. For example, the 3'-terminal nucleotide of the nucleic acid sequence encoding the fragment of signal peptide pelB may be located in R5. For example, when the released linker is linked to the released HC, the nucleic acid sequence encoding the full-length signal peptide pelB can be formed by linking the nucleic acid sequence encoding the fragment of signal peptide pelB contained in the released linker to the nucleic acid sequence encoding the fragment of signal peptide pelB contained in the released HC.

[0112] In the present invention, the linker may have a length of about 50 to about 200 bases. For example, the linker may have a length of about 50 to about 200 bases, about 50 to about 180 bases, about 50 to about 160 bases, about 50 to about 140 bases, about 50 to about 120 bases, about 50 to about 100 bases, about 50 to about 90 bases, about 50 to about 80 bases, about 50 to about 75 bases, about 50 to about 70 bases, or about 50 to about 60 bases.

[0113] In the present invention, in the above-mentioned ligation product for display in 6), the above-mentioned LC may be upstream of the above-mentioned linker, and the above-mentioned linker may be upstream of the above-mentioned HC. In the present invention, the above-mentioned upstream may be the 5' end of the nucleotide sequence.

[0114] In the present invention, 2) may include cryopreserving the light chain component bacterial library and / or the heavy chain component bacterial library. In the present invention, 7) may include cryopreserving the display bacterial library. In the present invention, the cryopreservation may be performed at a temperature below -18°C, for example below -80°C.

[0115] In the present invention, the method may include 8) thawing and culturing the above-mentioned cryopreserved display bacterial library, and constructing the above-mentioned phage library using the cultured display bacterial library.

[0116] In the present invention, the first polynucleotide may comprise the structure R1-LC-R2 in a 5'→3' direction, the second polynucleotide may comprise the structure R3-linker-R4 in a 5'→3' direction, the third polynucleotide may comprise the structure R5-HC-R6 in a 5'→3' direction, and the display vector may comprise the structure R7-display vector fragment-R8 in a 5'→3' direction, wherein R1, R2, R3, R4, R5, R6, R7 and R8 are recognition sites for restriction endonuclease.

[0117] In the present invention, the end cleaved by the restriction endonuclease of R2 can recognize and link to the end cleaved by the restriction endonuclease of R3, and does not recognize or link to the end cleaved by any of the restriction endonucleases of R1, R4, R5, R6, R7 and R8. In the present invention, R2 may be the same as R3.

[0118] In the present invention, the end cleaved by the restriction endonuclease R4 can recognize and link to the end cleaved by the restriction endonuclease R5, and does not recognize or link to the end cleaved by any of the restriction endonucleases R1, R2, R3, R6, R7 and R8. In the present invention, R4 may be the same as R5.

[0119] In the present invention, the end cleaved by the restriction endonuclease R6 can recognize and link to the end cleaved by the restriction endonuclease R7, and does not recognize or link to the end cleaved by any of the restriction endonucleases R1, R2, R3, R4, R5 and R8. In the present invention, R6 may be the same as R7.

[0120] In the present invention, the end cleaved by the restriction endonuclease of R8 can recognize and link to the end cleaved by the restriction endonuclease of R1, and does not recognize or link to the end cleaved by any of the restriction endonucleases of R2, R3, R4, R5, R6 and R7. In the present invention, R8 may be the same as R1.

[0121] In the present invention, any of the ends cleaved by the restriction endonuclease R1, R2, R3, R4, R5, R6, R7 and R8 may be non-palindromic sequences.

[0122] In the case of the selection of endonuclease recognition sites (e.g., in the case of R1, R2, R3, R4, R5, R6, R7 and R8), sequences that are essentially not included in the variable region of the antibody (e.g., the light chain variable region or the heavy chain variable region) may be selected so as to preserve the integrity of the antibody variable region as much as possible and prevent the destruction (e.g., biodegradation) of the antibody gene pool in the case of enzymatic digestion. Note that the ends formed after cleavage by the restriction endonuclease of the above nuclease recognition sites may be non-palindromic sequences to prevent self-ligation and further achieve a reduction in non-target ligation. Note that the selection of the above endonuclease recognition sites allows for directed ligation of multiple fragments to improve ligation efficiency.

[0123] In the present invention, two or more (e.g., two, three, four, five, six, seven or eight) of R1, R2, R3, R4, R5, R6, R7 and R8 above can be recognized and cleaved by the same restriction endonuclease.

[0124] For example, in the present invention, the above R1, R2, R3, R4, R5 and R8 can be recognized and cleaved by the same restriction endonuclease. For example, the above R6 and R7 can be recognized and cleaved by the same restriction endonuclease. In some cases, the restriction endonuclease that recognizes the above R1, R2, R3, R4, R5 and R8 may be different from the restriction endonuclease that recognizes the above R6 and R7.

[0125] In the present invention, the restriction endonuclease may be selected from SfiI, BsmBI and Esp3I. In the present invention, the BsmBI and Esp3I may be isozymes capable of recognizing the same restriction endonuclease recognition site.

[0126] In the present invention, for example, the above R1, R2, R3, R4, R5 and R8 can be recognized and cleaved by SfiI. In the present invention, for example, the above R6 and R7 can be recognized and cleaved by BsmBI and / or Esp3I.

[0127] For example, SfiI can recognize the sequence (5'-3') GGCCNNNN / NGGCC (SEQ ID NO:99) consisting of 13 bases that form an overhang sequence (e.g., a single-stranded sequence containing 3 bases) at the 3' end when digested with the enzyme, where N represents one of the four bases GATC. Therefore, all 64 different sequences can be recognized by SfiI.

[0128] For example, BsmBI and Esp3I can recognize the sequence (5'-3') CGTCTCN / NNNNN (SEQ ID NO:100) consisting of 12 bases that forms a 5'-end overhang (e.g., a single-stranded sequence containing 4 bases) when enzymatically digested, where N represents any one of the four bases GATC. Therefore, all 264 different sequences can be recognized by BsmBI and Esp3I.

[0129] In the present invention, the above R1 may have a nucleic acid sequence represented by SEQ ID NO: 1. In the present invention, the above R2 may have a nucleic acid sequence represented by SEQ ID NO: 2. In the present invention, the above R3 may have a nucleic acid sequence represented by SEQ ID NO: 2. In the present invention, the above R4 may have a nucleic acid sequence represented by SEQ ID NO: 3. In the present invention, the above R5 may have a nucleic acid sequence represented by SEQ ID NO: 3. In the present invention, the above R6 may have a nucleic acid sequence represented by SEQ ID NO: 4. In the present invention, the above R7 may have a nucleic acid sequence represented by SEQ ID NO: 4. In the present invention, the above R8 may have a nucleic acid sequence represented by SEQ ID NO: 1.

[0130] In the present invention, the above-mentioned light chain or light chain fragment may comprise a light chain variable region portion and / or a light chain constant region portion. In the present invention, the above-mentioned heavy chain or heavy chain fragment may comprise a heavy chain variable region portion and / or a heavy chain constant region portion.

[0131] For example, the LC may comprise a polynucleotide encoding the light chain variable region VL of the light chain or light chain fragment. For example, the first polynucleotide may comprise a polynucleotide encoding the light chain variable region VL of the light chain or light chain fragment. The first polynucleotide may be linked at its 5' end to the R1 and at its 3' end to the R2, and the light chain storage vector fragment may be linked at its 5' end to the R3 and at its 3' end to the R8.

[0132] For example, the HC may comprise a polynucleotide encoding the heavy chain variable region VH and the heavy chain constant region CH1 of the heavy chain or heavy chain fragment. For example, the third polynucleotide may comprise a polynucleotide encoding the heavy chain variable region VH and the heavy chain constant region CH1 of the heavy chain or heavy chain fragment. The third polynucleotide may be linked at its 5' end to the R5 and at its 3' end to the R6, and the heavy chain conservation vector fragment may be linked at its 5' end to the R7 and at its 3' end to the R4.

[0133] Also, for example, the HC may comprise a polynucleotide encoding the heavy chain variable region VH of the heavy chain or heavy chain fragment. For example, the third polynucleotide may comprise a polynucleotide encoding the heavy chain variable region VH of the heavy chain or heavy chain fragment. In this case, the heavy chain storage vector fragment may comprise a polynucleotide encoding the CH1 of the heavy chain constant region of the heavy chain or heavy chain fragment. The third polynucleotide may be linked at its 5' end to the R5 and at its 3' end to the R6, and the heavy chain storage vector fragment may be linked at its 5' end to the R7 and at its 3' end to the R4.

[0134] In the present invention, the above-mentioned antibodies or fragments thereof may include Fab, Fab', (Fab)2 and / or (Fab')2.

[0135] In the present invention, the above-mentioned ligation product for display in 7) has a ligation transformation efficiency of at least 10 8clones / μg polynucleotide (e.g., at least 10 9 clones / μg polynucleotide, at least 10 10 clones / μg polynucleotide, at least 10 11 clones / μg polynucleotide, at least 10 12 The amount of the clones may be up to 1000 clones / μg polynucleotide.

[0136] In the present invention, 2) may include enzymatically digesting the first polynucleotide with a restriction endonuclease that recognizes R1 and R2, ligating the enzymatically digested first polynucleotide to a light chain storage vector fragment to form a light chain storage ligation product, and introducing the product into the first bacterium to obtain the light chain component bacterial library, wherein the light chain storage vector comprises R1 and R2, and enzymatically digesting the light chain storage vector with a restriction endonuclease that recognizes R1 and R2 to obtain the light chain storage vector fragment.

[0137] In the present invention, the length of the LC may be greater than about 600bp. For example, it may be greater than about 650bp, greater than about 680bp, or greater than about 700bp. In the present invention, the length of the first polynucleotide may be greater than about 600bp. For example, it may be greater than about 650bp, greater than about 680bp, or greater than about 700bp. In the present invention, the length of the light chain-preserving vector fragment may be greater than about 900bp, for example, greater than about 1000bp, greater than about 1500bp, greater than about 1800bp, or greater than about 2100bp. In the present invention, the length of the light chain-preserving vector fragment may be obviously different from that of the LC. For example, the length of the light chain-preserving vector fragment may be significantly distinguished from that of the LC by polyacrylamide gel electrophoresis.

[0138] In the present invention, the light chain preservation vector may be derived from any vector, for example, any amplifiable and / or easily preserved vector. In some cases, the vector to be used as the light chain preservation vector may have characteristics such as high copy number, low molecular weight, etc. For example, the light chain preservation vector may be a pUC vector. In the present invention, the pUC vector may be a pUC19 vector (whose structural diagram is shown in FIG. 1) or may be derived from a pUC19 vector. In the present invention, the pUC vector may be a pMD19-T vector or may be derived from a pMD19-T vector.

[0139] In the present invention, the restriction endonucleases that recognize R1 and R2 may include SfiI.

[0140] In the present invention, the method may include 2) enzymatically digesting the third polynucleotide with a restriction endonuclease that recognizes R5 and R6, ligating the enzymatically digested third polynucleotide to a heavy chain-preserving vector fragment to form a heavy chain-preserving ligation product, and introducing the product into the third bacterium to obtain the heavy chain component bacterial library, wherein the heavy chain-preserving vector comprises R5 and R6, and enzymatically digesting the heavy chain-preserving vector with a restriction endonuclease that recognizes R5 and R6 to obtain the heavy chain-preserving vector fragment.

[0141] In the present invention, the length of the HC may be greater than about 320bp. For example, it may be greater than about 350bp, greater than about 380bp, or greater than about 400bp. In the present invention, the length of the third polynucleotide may be greater than about 320bp. For example, it may be greater than about 350bp, greater than about 380bp, or greater than about 400bp. In the present invention, the length of the heavy chain-preserving vector fragment may be greater than about 900bp, for example, greater than about 1000bp, greater than about 1500bp, greater than about 1800bp, or greater than about 2100bp. In the present invention, the length of the heavy chain-preserving vector fragment may be clearly different from that of the HC. For example, the length of the light chain-preserving vector fragment may be significantly distinguished from that of the HC by polyacrylamide gel electrophoresis.

[0142] In the present invention, the above-mentioned heavy chain preservation vector may be derived from any vector, for example, any amplifiable and / or easily preserved vector. In some cases, the above-mentioned vector to be used as a heavy chain preservation vector may have characteristics such as high copy number, low molecular weight, etc. For example, the above-mentioned heavy chain preservation vector may be a pUC vector. In the present invention, the above-mentioned pUC vector may be a pUC19 vector (whose structural diagram is shown in FIG. 1) or may be derived from a pUC19 vector. In the present invention, the above-mentioned pUC vector may be a pMD19-T vector or may be derived from a pMD19-T vector.

[0143] In the present invention, to construct the above-mentioned heavy chain conservation vector, the above-mentioned pUC vector or a vector derived from pUC may be engineered / modified.For example, one or more endonuclease recognition sites in the above-mentioned vector (e.g., one or more BsmBI recognition sites therein) may be removed by site-directed mutagenesis.In some cases, one or more endonuclease recognition sites may be added to the above-mentioned vector by site-directed mutagenesis (e.g., one or more BsmBI recognition sites may be added at selected positions).

[0144] In one embodiment, a modified vector (e.g., a modified pUC vector) can be obtained by removing one or more BsmBI recognition sites originally contained in the vector by site-directed mutagenesis and adding one or more additional BsmBI recognition sites at another position in the vector.

[0145] In the present invention, the above-mentioned heavy chain conservation vector contains a BsmBI recognition site, and may contain one BsmBI recognition site.

[0146] In the present invention, the restriction endonucleases that recognize the above R5 and R6 may include SfiI, BsmBI, and / or Esp3I. In some cases, the restriction endonucleases that recognize the above R5 and R6 are BsmBI and / or Esp3I.

[0147] In the present invention, 2) may include ligating the second polynucleotide to a vector fragment to form a linker-preserving vector (for example, based on the Takara TA clone product specification), and introducing the linker-preserving vector into the second bacterium to obtain the linker component bacterium. In the present invention, the linker-preserving vector may include the R3 and R4 sites.

[0148] In the present invention, the length of the linker may be greater than about 70 bp, for example, greater than about 72 bp, or greater than about 90 bp. In the present invention, the length of the second polynucleotide may be greater than about 80 bp, for example, greater than about 90 bp, greater than about 100 bp, or greater than about 120 bp. In the present invention, the length of the vector fragment may be greater than about 800 bp.

[0149] In the present invention, the vector fragment for constructing the linker-storing vector may be derived from any vector, for example, any amplifiable and / or easily preserved vector. In some cases, the vector for constructing the linker-storing vector may have characteristics such as high copy number, low molecular weight, etc. For example, the vector fragment for constructing the linker-storing vector may be derived from a pUC vector. In the present invention, the pUC vector may be a pUC19 vector (whose structural diagram is shown in FIG. 1) or may be derived from a pUC19 vector. In the present invention, the pUC vector may be a pMD19-T vector or may be derived from a pMD19-T vector.

[0150] In the present invention, the above-mentioned pUC19 vector or pMD19-T vector includes vectors derived therefrom but modified / altered.

[0151] In the present invention, 4) may comprise obtaining the released LC by enzymatically digesting the light chain component plasmid with a restriction endonuclease that recognizes R1 and R2. In the present invention, the restriction endonuclease that recognizes R1 and R2 may comprise SfiI.

[0152] In the present invention, 4) may include obtaining the released HC by performing an enzymatic digestion treatment on the heavy chain component plasmid using a restriction endonuclease that recognizes the R5 and R6. In the present invention, the restriction endonuclease that recognizes the R5 and R6 may include SfiI, BsmBI and / or Esp3I.

[0153] In some cases, in the present invention, 4) may include obtaining the released linker by performing an enzymatic digestion treatment on the linker-preserving vector using a restriction endonuclease that recognizes R3 and R4.

[0154] For example, the linker-storing vector can be directly digested with a restriction endonuclease (e.g., SfiI) that recognizes R3 and R4 to obtain the released linker. In the present invention, the length of the linker may be about 72 bp or more, for example, about 90 bp or more.

[0155] In some cases, in the present invention, 4) may include obtaining an amplification product containing the linker, the R3 and the R4 by the linker-preserving vector, and obtaining the released linker by performing an enzymatic digestion treatment on the amplification product using a restriction endonuclease that recognizes the R3 and R4.

[0156] For example, the above-mentioned amplification product, which may have a length of about 800 bp or more including the above-mentioned linker, the above-mentioned R3 and the above-mentioned R4, can be obtained by a method such as PCR. For example, the length may be about 900 bp or more, about 1000 bp or more, about 1200 bp or more. In the present invention, the above-mentioned released linker can be obtained by enzymatically digesting the above-mentioned amplification product using a restriction endonuclease (e.g., SfiI) that recognizes the above-mentioned R3 and R4. In the present invention, the length of the above-mentioned linker can be about 72 bp or more, about 90 bp or more. In the present invention, the above-mentioned amplification product has a length that is clearly different from that of the above-mentioned linker. In this way, a single above-mentioned linker can be obtained more easily and effectively. For example, the above-mentioned amplification product can be significantly distinguished from the above-mentioned linker by polyacrylamide gel electrophoresis in length.

[0157] In the present invention, the restriction endonucleases that recognize R3 and R4 may include SfiI.

[0158] In the present invention, 5) may include performing an enzymatic digestion treatment on the display vector using a restriction endonuclease that recognizes the above R7 and R8 to release the above display vector fragment. In the present invention, the above restriction endonuclease that recognizes the above R7 and R8 may include SfiI, BsmBI, and / or Esp3I.

[0159] In the present invention, the display vector may be derived from any suitable vector, such as a pComb3x vector. The pComb3x vector may be modified to be used for the purpose of the present invention. For example, the pComb3x vector may contain one SfiI recognition site at the 5' end and one SfiI recognition site at the 3' end, and in the modification process, the SfiI recognition site at the 3' end in the pComb3x vector may be removed by site-directed mutagenesis. In some cases, the site-directed mutagenesis does not affect the in-frame expression of proteins (e.g., antibody heavy chain fragments and / or antibody light chain fragments) in the vector. For example, the mutation may be a nonsense mutation, such as one that only changes the base sequence but does not change the amino acid sequence.

[0160] In the present invention, when the display vector is subjected to enzymatic digestion using restriction endonucleases that recognize R1, R2, R3, R4, R5 and R8, three different enzymatic digestion fragments can be obtained. For example, the display vector may contain recognition sites for restriction endonucleases recognized by three SfiI. When the display vector is subjected to enzymatic digestion using SfiI, three different enzymatic digestion fragments can be obtained.

[0161] In the present invention, the restriction endonucleases that recognize R1, R2, R3, R4, R5, and R8 may include SfiI. In the present invention, when the display vector is subjected to an enzymatic digestion treatment using a restriction endonuclease that recognizes R6 and R7, the display vector can be linearized.

[0162] In the present invention, the restriction endonucleases recognizing R6 and R7 above may include BsmBI and / or Esp3I.

[0163] In the present invention, when the display vector is subjected to enzymatic digestion using the restriction endonucleases that recognize R1, R2, R3, R4, R5, R6, R7 and R8, four different enzymatic digestion fragments are obtained. For example, the display vector may contain three restriction endonuclease recognition sites recognized by SfiI and one restriction endonuclease recognition site recognized by BsmBI and / or Esp3I. When the display vector is subjected to enzymatic digestion using SfiI, BsmBI and / or Esp3I, the four different enzymatic digestion fragments are obtained.

[0164] For example, the released LC can be obtained by the restriction endonucleases R1 and R2, and the released HC can be obtained by the restriction endonucleases R5 and R6.

[0165] In the present invention, the above restriction endonucleases recognizing the above R1, R2, R3, R4, R5, R6, R7 and R8 may include SfiI, BsmBI and / or Esp3I.

[0166] In the present invention, the vector (e.g., the display vector or storage vector) may comprise or encode one or more suitable markers (e.g., markers used for purification / recognition / screening), which may be, for example, His tag, Flag tag, fluorescent protein, selection antibiotic, and / or avidin.

[0167] In the present invention, 2) includes sampling and detecting the light chain component bacterial library, the linker component bacterial library and / or the heavy chain component bacterial library, thereby being able to identify the library volume and / or quality of the light chain component bacterial library, the linker component bacterial library and / or the heavy chain component bacterial library.

[0168] In the present invention, the light chain component bacterial library comprises at least about 10 6 (e.g., at least about 10 7 Pieces, at least about 10 8 Pieces, at least about 10 9 Pieces, at least about 10 10 Pieces, at least about 10 11 Pieces, at least about 10 12 The clone may contain different clones (one or more).

[0169] In the present invention, the heavy chain component bacterial library comprises at least about 10 7 (e.g., at least about 10 8 Pieces, at least about 10 9 Pieces, at least about 10 10 Pieces, at least about 10 11 Pieces, at least about 10 12 The clone may contain different clones (one or more).

[0170] In the present invention, the effective cloning rate in the light chain component bacterial library described above may be at least about 70% (e.g., at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%).

[0171] In the present invention, the effective cloning rate in the above-mentioned heavy chain component bacterial library may be at least about 70% (e.g., at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%).

[0172] In the present invention, 2) may include measuring the library capacity and / or quality of the display bacterial library based on the library capacity, the linker component bacterial and / or the quality of the light chain component bacterial library and / or the heavy chain component bacterial library.

[0173] In the present invention, the display bacterial library comprises at least about 10 10 (e.g., at least about 10 11 Pieces, at least about 10 12 Pieces, at least about 10 13 Pieces, at least about 10 14 Pieces, at least about 10 15 Pieces, at least about 10 16 The clone may contain different clones (one or more).

[0174] In the present invention, the effective cloning rate in the above-mentioned display bacterial library may be at least about 70% (e.g., at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%).

[0175] In the present invention, in the above display bacterial library, the bacteria can be liquid cultured. The culture time of the above liquid culture may be not more than about 8 hours, for example, not more than about 4 hours, not more than about 5 hours, not more than about 6 hours or not more than about 7 hours. In the present invention, the above liquid culture operation is convenient. In some cases, in the above display bacterial library, the bacteria can be cultured in a dish by taking a small amount of bacterial liquid, and then the bacterial colony is selected. The culture time of the above dish culture may be about 12-18 hours, for example, about 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours or 18 hours. In the present invention, the above dish culture can be used to select bacterial colonies (e.g., single clones) and then perform sequencing analysis. In the present invention, the above dish culture can reduce the number of dominant clones.

[0176] In the present invention, the first polynucleotide and the third polynucleotide may be obtained from a sample material. In the present invention, the sample material may include material derived from a peripheral blood lymphocyte sample. In the present invention, the peripheral blood lymphocytes may be human peripheral blood lymphocytes. In the present invention, the sample material is not limited to the peripheral blood lymphocyte sample, but may be derived from any other tissue and / or cell.

[0177] In the present invention, the sample material may comprise total RNA and / or mRNA derived from the sample.

[0178] In the present invention, 8) may include preparing the above-mentioned phage library by contacting the above-mentioned display bacterial library with a helper phage.

[0179] On the other hand, the present invention provides a phage library produced by the above method.

[0180] In the present invention, the phage library comprises at least about 10 10 (e.g., at least about 10 11 Pieces, at least about 10 12 Pieces, at least about 10 13 Pieces, at least about 10 14 Pieces, at least about 10 15 Pieces, at least about 10 16 In the present invention, the phage library may contain at least about 10 different clones. 10 species (e.g., at least about 10 11 Seeds, at least about 10 12 Seeds, at least about 10 13 Seeds, at least about 10 14 Seeds, at least about 10 15 Seeds, at least about 10 16 Different antibodies or antibody fragments (of different species or more) can be displayed.

[0181] On the other hand, the present invention provides a method for screening an antibody or an antibody fragment, which comprises using the above-mentioned phage library.

[0182] For example, the antibody fragment may be a Fab. For example, the antibody or antibody fragment may specifically bind to TNFα, IL-6, IL6R, IL17-FR, CD38, GMCSF and Siglec3.

[0183] The following examples are merely illustrative of the fusion proteins, preparation methods and uses of the present invention, without being bound by any theory, and are not intended to limit the scope of the present invention.

[0184] Working Example Example 1. Phage surface antibody (Fab) display library for constructing human PBMC 1.1 Obtaining total RNA / mRNA from immune samples Total RNA was extracted from human peripheral blood lymphocytes, and then mRNA was isolated from the total RNA (Takara Cat# Z652N / 636592, see the product specifications for specific test steps).

[0185] 1.2 Primer design and synthesis Primers for human heavy chain variable region VH, light chain KLC (full-length Kappa light chain), and light chain LLC (full-length Lambda light chain) were designed with reference to "Phage Display" (A Laboratory Manual, ISBN 0-87969-546-3). Here, the light chain has the nucleotide sequence of R1 GGCCCAGGCGGCC (SEQ ID NO: 1) at the 5'-end of the forward primer and the nucleotide sequence of R2 GGCCACATAGGCC (SEQ ID NO: 2) at the 5'-end of the reverse primer, and the heavy chain variable region has the nucleotide sequence of R5 GGCCCAACCGGCC (SEQ ID NO: 3) at the 5'-end of the forward primer and the nucleotide sequence of R6 at the 5'-end of the reverse primer. CGTCTCCTCAGC (SEQ ID NO: 4). The primers were synthesized by Kinetics Co., Ltd.

[0186] Using the pComb3x vector as a template, forward and reverse primers were designed to amplify the linker, with the forward primer carrying the nucleotide sequence of R3 GGCCACATAGGCC (SEQ ID NO: 2) at its 5'-end and the reverse primer carrying the nucleotide sequence of R4 GGCCCAACCGGCC (SEQ ID NO: 3) at its 5'-end.

[0187] For specific primer sequences, see Table 1-1 below.

[0188] TIFF0007671502000001.tif75170

[0189] 1.3 Obtaining the first and third polynucleotides The component antibody gene pools were amplified using a two-step method.

[0190] In the first step, the mRNA obtained in Example 1.1 was used as a template and reverse transcription was performed using Promega's MMLV to synthesize cDNA (based on the Promega product specifications, where the primer was Thermo Cat# N8080127 and the reverse transcriptase was Promega Cat# M1701).

[0191] In the second step, the cDNA obtained in the first step was used as a template, and the primers obtained in Example 1.2 were used to amplify the KLC, LLC and VH gene pools of the component antibodies by PCR (Takara Cat# RR900A, based on the company's product specifications). After purification and recovery by gel electrophoresis (using Axygen's gel recovery kit, based on the procedure described in the "Molecular Cloning Experimental Guide"), the PCR products, i.e., the KLC fragment (i.e., the first polynucleotide of the present invention), the LLC fragment (i.e., the first polynucleotide of the present invention) and the VH fragment (i.e., the third polynucleotide of the present invention), were obtained, respectively.

[0192] 1.4 Construction of storage vectors 1.4.1 Primer design The primers were designed with reference to the contents of Example 1.2.

[0193] Design and synthesize primers to obtain the storage vector. Specific primer sequences may be found in Table 1-2 below.

[0194] TIFF0007671502000002.tif47170

[0195] 1.4.2 PCR Amplification PCR was performed using the 1 kb long human IgG1 Fc (SEQ ID NO: 87) as a template and the R1-1 kb-R2 forward and R1-1 kb-R2 reverse primers prepared in Example 1.4.1, and the PCR product, R1-1 kb-R2 (SEQ ID NO: 88), was obtained after purification and recovery by gel electrophoresis (using Axygen gel recovery kit).

[0196] Using pComb3x vector as template, PCR was performed using R3-linker-R4 forward primer (SEQ ID NO: 83) and R3-linker-R4 reverse primer (SEQ ID NO: 84), and after purification and recovery by gel electrophoresis (by Axygen gel recovery kit), a PCR product, namely R3-linker-R4 (SEQ ID NO: 90), was obtained, which is the above-mentioned second polynucleotide of the present invention, wherein said linker can be 72 bp in length, and its nucleotide sequence is represented by SEQ ID NO: 89.

[0197] Using 1 kb long human IgG1 Fc (SEQ ID NO: 87) as a template, PCR was performed using the forward primer R5-1kb-R6 and the reverse primer R5-1kb-R6 prepared in Example 1.4.1, and the PCR product, i.e., R5-1kb-R6 (SEQ ID NO: 91), was obtained after purification and recovery by gel electrophoresis.

[0198] 1.4.3 Construction of light chain and heavy chain storage vectors The R1-1kb-R2 fragment prepared in 1.4.2 was inserted into the pMD19-T vector by the TA cloning method (TA cloning kit, purchased from Takara), to obtain the light chain storage vector DDB-R1-1kb-R2 for inserting the full-length light chain gene pool, and its vector map is shown in Figure 3.

[0199] By inserting the R5-1kb-R6 fragment prepared in 1.4.2 into the pMD19-T vector by the method of TA cloning (TA cloning kit, purchased from Takara), an R5-1kb-R6 fragment-containing vector was obtained, and the original BsmBI enzyme digestion site in this vector was removed by primer mutation using this vector as a template to obtain the heavy chain conservation vector DDB-R5-1kb-R6 for inserting the VH gene pool, the vector map of which is shown in Figure 5.

[0200] Specific primer sequences may be seen in Tables 1-3 below.

[0201] TIFF0007671502000003.tif31170

[0202] 1.4.4 Constructing linker-conserved vectors to obtain linker component bacteria By inserting the R3-linker-R4 prepared in Example 1.4.2 into the pMD19-T vector by the method of TA cloning (TA cloning kit, purchased from Takara), the linker-preserving vector DDB-R3-linker-R4 is obtained, the vector map of which is shown in Figure 4. The linker-preserving vector is used to transform TG1 competent bacteria (Lucigen), spread on a culture plate and cultured overnight at 37°C, then transferred to bacterial colonies for sequencing, and the bacterial colonies are picked up to obtain linker component bacteria. The linker component bacteria can be frozen and prepared.

[0203] 1.5 Obtaining component bacterial libraries 1.5.1 Obtaining the light chain component bacterial library The target light chain fragment (about 0.65 kb) was obtained by enzymatically digesting the first polynucleotide (containing KLC and LLC) prepared in Example 1.3 with restriction endonucleases R1 and R2.

[0204] The light chain storage vector DDB-R1-1kb-R2 prepared in Example 1.4 was enzymatically digested with restriction endonucleases R1 and R2 to obtain a light chain storage vector fragment (approximately 2.7kb).

[0205] The obtained target light chain fragment is mixed with the light chain conservation vector fragment, and the light chain conservation ligation product is obtained by ligation with ligase T4 DNA ligase (purchased from NEB, Thermo), and the above light chain conservation ligation product is transformed into TG1 competent bacteria (Lucigen, Cat# 60502-2, according to the manufacturer's product specifications), spread on an ampicillin-resistant Petri dish (Thermo, Cat#240845), cultivated at 37°C overnight, transferred to bacterial colonies for sequencing, and all bacterial colonies are picked up to obtain a light chain component bacterial library. The quality of the light chain component bacterial library can be detected and / or the light chain component bacterial library can be frozen and prepared.

[0206] 1.5.2 Obtaining heavy chain component bacterial libraries The target heavy chain variable region fragment (about 0.35 kb) was obtained by enzymatically digesting the third polynucleotide prepared in Example 1.3 with restriction endonucleases R5 and R6.

[0207] The heavy chain storage vector DDB-R5-1kb-R6 prepared in Example 1.4 was enzymatically digested with restriction endonucleases R5 and R6 to obtain a heavy chain storage vector fragment (about 2.7 kb).

[0208] The obtained target heavy chain variable region fragment is mixed with heavy chain conservation vector fragment, and the heavy chain conservation ligation product is obtained by ligation with ligase T4 DNA ligase (purchased from NEB, Thermo), and the above heavy chain conservation ligation product is transformed into TG1 competent bacteria (Lucigen, Cat# 60502-2, according to the manufacturer's product specifications), spread on ampicillin-resistant Petri dishes (Thermo, Cat# 240845), and cultured at 37 ° C overnight, and then pick the bacterial colonies for sequencing, and all the bacterial colonies are picked up, and a heavy chain component bacterial library is obtained. The quality of the heavy chain component bacterial library can be detected and / or the heavy chain component bacterial library can be frozen and prepared.

[0209] 1.6 Obtaining light chain component plasmids, heavy chain component plasmids and linker fragments The light chain component plasmids and the heavy chain component plasmids were obtained by extracting the plasmids in the light chain component bacterial library prepared in Example 1.5.1 and the heavy chain component bacterial library prepared in Example 1.5.2, respectively, using a plasmid extraction kit (purchased from Axygen).

[0210] The light chain component plasmid prepared in Example 1.5.1 was enzymatically digested with restriction endonucleases R1 and R2, and the light chain insert fragment LC was obtained after purification and recovery by gel electrophoresis.

[0211] The heavy chain component plasmid prepared in Example 1.5.2 was enzymatically digested with restriction endonucleases R5 and R6, and the heavy chain insert fragment HC was obtained after purification and recovery by gel electrophoresis.

[0212] The linker component plasmid was obtained by extracting the plasmid in the linker component bacteria prepared in Example 1.4.4 using a plasmid extraction kit (purchased from Axygen). The linker component plasmid or the linker storage vector in Example 1.4.4 was used as a template to amplify a 0.8 kb linker-containing fragment using the linker forward primer (SEQ ID NO: 79) and the linker reverse primer (SEQ ID NO: 80), and the 0.8 kb PCR product was enzymatically digested with restriction endonucleases R3 and R4, and after purification and recovery by gel electrophoresis (short fragment gel recovery kit, purchased from Shanghai Lifefeng Biotech Co., LTD, Cat# DK402), a linker fragment of 72 pb was obtained.

[0213] 1.7 Getting the display vector The pComb3x vector, whose vector map is shown in FIG. 6, was purchased, where the modified pComb3x-fab vector map used for the display of antibody Fab is shown in FIG.

[0214] The SfiI enzyme digestion site at the 3' end of the Fab gene was removed in the pComb3x-fab vector by nonsense mutation.

[0215] Then, in the vector in which the nonsense mutation had occurred, an enzyme digestion site for restriction endonuclease R2 was added downstream of the light chain stop codon, and an enzyme digestion site for restriction endonuclease R5 was introduced by nonsense mutation at the end of the heavy chain variable region signal peptide, thereby obtaining the modified display vector DDB-R1R2R5R6, the map of which is shown in FIG. 8.

[0216] 1.8 Preparation of display bacterial library A 3.6 kb display vector fragment was obtained by enzymatically digesting the display vector DDB-R1R2R5R6 prepared in Example 1.7 with restriction endonuclease R7 and restriction endonuclease R8.

[0217] The light chain insert fragment LC (0.65 kb), heavy chain insert fragment HC (0.35 kb), and linker fragment (72 bp) obtained in Example 1.6 were mixed with the above-mentioned display vector fragment (3.6 kb) in a molecular ratio of 1:1:1:1, and ligated with T4 DNA ligase at 20°C for more than 20 hours to obtain a ligated product for display.

[0218] The ligation products were purified by PCR-Clean-up, transferred into TG1 competent bacteria (Lucigen, Cat# 60502-2, according to the manufacturer's product specifications), and incubated in 2YT medium without antibiotics at 37°C with shaking at 250 rpm for 60 minutes, then spread on ampicillin-resistant Petri dishes (Thermo, Cat# 240845) and grown overnight at 37°C. Bacterial colonies were picked and sequenced, and all bacterial colonies grown on the Petri dishes were picked up to obtain a display bacterial library. The display bacterial library can be stored and prepared.

[0219] 1.9 Preparation of display antibody phage library An appropriate amount of the bacterial liquid was taken from the display bacterial library prepared in Example 1.8, and cultured in 2YT culture medium (containing 100 μg / ml ampicillin and 2% glucose) at 37° C. until OD 600 The bacteria were cultured so that the MOI was 0.5. Then, M13KO7 helper phage (purchased from NEB, Cat# N0315S, MOI was about 10-20) was added to the bacterial solution, mixed uniformly, and then left to stand at 37°C for 30 minutes, followed by shaking at 37°C and 250 rpm for 30 minutes. The M13KO7 helper phage-containing culture supernatant was centrifuged and discarded, and the bacteria were resuspended in a culture solution (containing ampicillin and kanamycin) four times the initial volume of the bacterial solution, and shaken overnight at 30°C and 250 rpm. On the second day, the phages were precipitated with PEG, collected, titrated, packaged, and stored. In this way, a display-type antibody phage library was obtained.

[0220] Example 2 Quality analysis of component bacterial libraries The quality of the component bacterial libraries prepared in Example 1.5 was analyzed, and the results are shown in Table 2.

[0221] TIFF0007671502000004.tif77170

[0222] When constructing the display bacterial library, the ratio of the light chain component bacterial library (KLC) to the light chain component bacterial library (LLC) is 2:1. From the above quality results, it can be estimated that the effective cloning rate of the display bacterial library is more than 84%. In addition, the library capacity obtained by randomly combining the above light chain component bacterial library with the heavy chain component bacterial library is theoretically up to 10 15 There was a possibility that it would become like this.

[0223] Example 3 Quality analysis of the display bacterial library 398 TG1 competent bacteria were transformed with 197 μg of the isolated and purified ligation product for display obtained in Example 1.8 (Lucigen, Cat# 60502-2, according to the manufacturer's product specifications), and incubated in 2YT medium without antibiotics at 37° C. with shaking at 250 rpm for 60 minutes, then spread onto 197 ampicillin-resistant Petri dishes (Thermo, Cat# 240845), incubated overnight at 37° C., and all bacterial colonies were obtained, packaged, and stored (i.e., the display bacterial library prepared in Example 1.8 was obtained). The display bacterial library was prepared by mixing 10 11 with a background cloning rate of 2%.

[0224] The quality of the display bacterial library was analyzed and the results are shown in Table 3.

[0225] TIFF0007671502000005.tif46170

[0226] A total of 158 available sequencing results in two batches in Table 3 were analyzed, in which it was found that there were 131 clones with the correct reading frame (including having the correct heavy chain variable region and light chain at the same time), which resulted in an effective cloning rate of the display bacterial library of 83%, consistent with the predicted results in Example 2.

[0227] Example 4 Construction of a phage surface antibody (Fab) display library of human PBMCs 4.1 Extraction of total RNA from immune material Total RNA (Qiagen's MicroRNA Extraction Kit, Cat# 74101, see kit specifications for specific test steps) was extracted from peripheral blood lymphocytes (purchased from miles-bio.com Cat# PB100C).

[0228] 4.2 Primer design and synthesis Primers for human heavy chain variable region VH, light chain KLC (full-length Kappa light chain), and light chain LLC (full-length Lambda light chain) were designed with reference to "Phage Display" (A Laboratory Manual, ISBN 0-87969-546-3). Here, the light chain has the nucleotide sequence of R1 GGCCCAGGCGGCC (SEQ ID NO: 1) at the 5'-end of the forward primer and the nucleotide sequence of R2 GGCCACATAGGCC (SEQ ID NO: 2) at the 5'-end of the reverse primer, and the heavy chain variable region has the nucleotide sequence of R5 GGCCCAACCGGCC (SEQ ID NO: 3) at the 5'-end of the forward primer and the nucleotide sequence of R6 at the 5'-end of the reverse primer. CGTCTCCTCAGC (SEQ ID NO: 4). The primers were synthesized by Kinetics Co., Ltd.

[0229] Using the pComb3x vector as a template, forward and reverse primers were designed to amplify the linker, with the forward primer carrying the nucleotide sequence of R3 GGCCACATAGGCC (SEQ ID NO. 2) at its 5'-end and the reverse primer carrying the nucleotide sequence of R4 GGCCCAACCGGCC (SEQ ID NO. 3) at its 5'-end.

[0230] Specific primer sequences may be seen in Table 4-1 below.

[0231] TIFF0007671502000006.tif75170

[0232] 4.3 Obtaining the first and third polynucleotides The component antibody gene pools were amplified using a two-step method.

[0233] In the first step, the total RNA obtained in Example 4.1 was used as a template and reverse transcription was performed using Promega's MMLV to synthesize cDNA (based on the Promega product specifications, where the primer was Thermo Cat# N8080127 and the reverse transcriptase was Promega Cat# M1701).

[0234] In the second step, the cDNA obtained in the first step was used as a template, and the primers obtained in Example 4.2 were used to amplify the KLC, LLC and VH gene pools of the component antibodies by PCR (Takara Cat# RR900A, based on the company's product specifications). After purification and recovery by gel electrophoresis (using Axygen's gel recovery kit, based on the procedure described in the Molecular Cloning Experimental Guide), the PCR products, i.e., the KLC fragment (i.e., the first polynucleotide of the present invention), the LLC fragment (i.e., the first polynucleotide of the present invention) and the VH fragment (i.e., the third polynucleotide of the present invention), were obtained, respectively.

[0235] 4.4 Construction of storage vectors 4.4.1 Primer design Primers were designed to obtain the storage vector. The specific primer sequences can be seen in Table 4-2 below.

[0236] TIFF0007671502000007.tif46170

[0237] 4.4.2 PCR amplification PCR was performed using the 1 kb long human IgG1 Fc (SEQ ID NO. 87) as a template and the primers R1-1kb-R2 forward and reverse primers R1-1kb-R2 prepared in Example 4.4.1, and the PCR product, R1-1kb-R2 (SEQ ID NO. 88), was obtained after purification and recovery by gel electrophoresis (using Axygen gel recovery kit).

[0238] Using pComb3x vector as template, PCR was performed using R3-linker-R4 forward primer (SEQ ID NO. 83) and R3-linker-R4 reverse primer (SEQ ID NO. 84), and after purification and recovery by gel electrophoresis (by Axygen gel recovery kit), a PCR product, namely R3-linker-R4 (SEQ ID NO. 95), was obtained, which is the above-mentioned second polynucleotide of the present invention, wherein said linker can be 90bp in length, and its nucleotide sequence is represented by SEQ ID NO.89.

[0239] Using 1 kb long human IgG1 Fc (SEQ ID NO. 87) as a template, PCR was performed using the forward primer R5-1kb-R6 and the reverse primer R5-1kb-R6 prepared in Example 4.4.1, and the PCR product, i.e., R5-1kb-R6 (SEQ ID NO. 91), was obtained after purification and recovery by gel electrophoresis.

[0240] 4.4.3 Construction of light chain and heavy chain storage vectors The R1-1kb-R2 fragment prepared in 4.4.2 was inserted into the pMD19-T vector by the TA cloning method (TA cloning kit, purchased from Takara), to obtain the light chain storage vector DDB-R1-1kb-R2 for inserting the full-length light chain gene pool, and its vector map is shown in Figure 3.

[0241] By inserting the R5-1kb-R6 fragment prepared in 4.4.2 into the pMD19-T vector using the TA cloning method (TA cloning kit, purchased from Takara), an R5-1kb-R6 fragment-containing vector was obtained. Using this vector as a template, the original BsmBI enzyme digestion site in this vector was removed by primer mutation to obtain the heavy chain conservation vector DDB-R5-1kb-R6 for inserting the VH gene pool, the vector map of which is shown in Figure 5.

[0242] Specific primer sequences may be seen in Table 4-3 below.

[0243] TIFF0007671502000008.tif30170

[0244] 4.4.4 Constructing linker-conserved vectors to obtain linker component bacteria By inserting the R3-linker-R4 prepared in Example 4.4.2 into the pMD19-T vector by the method of TA cloning (TA cloning kit, purchased from Takara), the linker-preserving vector DDB- R3-linker-R4 was obtained, and its vector map is shown in Figure 4. The linker-preserving vector was used to transform TG1 competent bacteria (Lucigen), spread on a culture plate and cultured overnight at 37°C, then transferred to bacterial colonies for sequencing, and the bacterial colonies were picked up to obtain linker component bacteria. The linker component bacteria can be frozen and prepared.

[0245] 4.5 Obtaining component bacterial libraries 4.5.1 Obtaining the light chain component bacterial library A target light chain fragment (about 0.65 kb) was obtained by enzymatically digesting the first polynucleotide (containing KLC and LLC) prepared in Example 4.3 with restriction endonucleases R1 and R2.

[0246] The light chain storage vector DDB-R1-1kb-R2 prepared in Example 4.4 was enzymatically digested with restriction endonucleases R1 and R2 to obtain a light chain storage vector fragment (approximately 2.7 kb).

[0247] The obtained target light chain fragment is mixed with the light chain conservation vector fragment, and the light chain conservation ligation product is obtained by ligation with ligase T4 DNA ligase (purchased from NEB, Thermo), and the above light chain conservation ligation product is transformed into TG1 competent bacteria (Lucigen, Cat# 60502-2, according to the manufacturer's product specifications), and then cultured in 2YT medium without antibiotics at 37°C, 250 rpm for 60 minutes with shaking, then spread on an ampicillin-resistant Petri dish (Thermo, Cat#240845), cultured overnight at 37°C, transferred to bacterial colonies for sequencing, and then all bacterial colonies are picked up to obtain a light chain component bacterial library. The quality of the light chain component bacterial library can be detected and / or the light chain component bacterial library can be frozen and prepared.

[0248] 4.5.2 Obtaining heavy chain component bacterial libraries The target heavy chain variable region fragment (about 0.35 kb) was obtained by enzymatically digesting the third polynucleotide prepared in Example 4.3 with restriction endonucleases R5 and R6.

[0249] The heavy chain storage vector DDB-R5-1kb-R6 prepared in Example 4.4 was enzymatically digested with restriction endonucleases R5 and R6 to obtain a heavy chain storage vector fragment (about 2.7 kb).

[0250] The obtained target heavy chain variable region fragment is mixed with the heavy chain conservation vector fragment, and the heavy chain conservation ligation product is obtained by ligation with ligase T4 DNA ligase (purchased from NEB, Thermo), and the above heavy chain conservation ligation product is transformed into TG1 competent bacteria (Lucigen, Cat# 60502-2, according to the manufacturer's product specifications), and is cultured in 2YT medium without antibiotics at 37°C and 250 rpm for 60 minutes with shaking, then spread on an ampicillin-resistant Petri dish (Thermo, Cat# 240845), and cultured overnight at 37°C, and the bacterial colonies are picked and sequenced, and all the bacterial colonies are picked up to obtain a heavy chain component bacterial library. The quality of the heavy chain component bacterial library can be detected and / or the heavy chain component bacterial library can be frozen and prepared.

[0251] 4.6 Obtaining light chain component plasmids, heavy chain component plasmids and linker fragments The light chain component plasmids and the heavy chain component plasmids were obtained by extracting the plasmids in the light chain component bacterial library prepared in Example 4.5.1 and the heavy chain component bacterial library prepared in Example 4.5.2, respectively, using a plasmid extraction kit (purchased from Axygen).

[0252] The light chain component plasmid prepared in Example 4.5.1 was enzymatically digested with restriction endonucleases R1 and R2, and the light chain insert fragment LC was obtained after purification and recovery by gel electrophoresis.

[0253] The heavy chain component plasmid prepared in Example 4.5.2 was enzymatically digested with restriction endonucleases R5 and R6, and the heavy chain insert fragment HC was obtained after purification and recovery by gel electrophoresis.

[0254] The linker component plasmid was obtained by extracting the plasmid in the linker component bacteria prepared in Example 4.4.4 using a plasmid extraction kit (purchased from Axygen). The linker component plasmid or the linker storage vector in Example 4.4.4 was used as a template to amplify a 0.8 kb linker-containing fragment using the linker forward primer (SEQ ID NO.96 or SEQ ID NO.97) and the linker reverse primer (SEQ ID NO.98), and then the 0.8 kb PCR product was enzymatically digested with restriction endonucleases R3 and R4, and purified and recovered by gel electrophoresis (short fragment gel recovery kit, purchased from Shanghai Lifefeng Biotech Co., LTD, Cat# DK402), resulting in a 90 pb linker fragment.

[0255] 4.7 Getting the Display Vector The pComb3x vector, whose vector map is shown in FIG. 6, was purchased, where the modified pComb3x-fab vector map used for the display of antibody Fab is shown in FIG.

[0256] The SfiI enzyme digestion site at the 3' end of the Fab gene was removed in the pComb3x-fab vector by nonsense mutation.

[0257] Then, in the vector in which the nonsense mutation had occurred, an enzyme digestion site for restriction endonuclease R2 was added downstream of the light chain stop codon, and an enzyme digestion site for restriction endonuclease R5 was introduced by nonsense mutation at the end of the heavy chain variable region signal peptide, thereby obtaining the modified display vector DDB-R1R2R5R6, the map of which is shown in FIG. 8.

[0258] 4.8 Preparation of display bacterial libraries A 3.6 kb display vector fragment was obtained by enzymatically digesting the display vector DDB-R1R2R5R6 prepared in Example 4.7 with restriction endonuclease R7 and restriction endonuclease R8.

[0259] The light chain insert fragment LC (0.65 kb), heavy chain insert fragment HC (0.35 kb), and linker fragment (90 bp) obtained in Example 4.6 were mixed with the above-mentioned display vector fragment (3.6 kb) in a molecular ratio of 1:1:1:1, and ligated with T4 DNA ligase at 20°C for more than 20 hours to obtain a ligated product for display.

[0260] The ligation products were purified by PCR-Clean-up, transferred to TG1 competent bacteria (purchased from Lucigen, Cat# 60502-2), and cultured in antibiotic-free 2YT culture medium at 37°C with shaking at 250 rpm for 60 minutes, then expanded to ampicillin-containing 2YT culture medium at a ratio of 1:20, cultured at 37°C with shaking at 250 rpm for 4.5 hours, and the bacteria were collected by centrifugation and frozen for storage, resulting in a display bacterial library. Before adding ampicillin and expanding the culture, a small amount of the bacterial liquid was removed and placed on a culture dish, cultured overnight at 37°C, and bacterial colonies were picked and sequenced. The display bacterial library can be stored and prepared.

[0261] 4.9 Preparation of display antibody phage library An appropriate amount of the bacterial liquid was taken from the display bacterial library prepared in Example 4.8, and cultured in 2YT culture medium (containing 100 μg / ml ampicillin and 2% glucose) at 37° C. until OD 600The bacteria were cultured so that the MOI was 0.5. Then, M13KO7 helper phage (purchased from NEB, Cat# N0315S, MOI was about 10-20) was added to the bacterial solution, mixed uniformly, and then allowed to stand at 37°C for 30 minutes. The M13KO7 helper phage-containing culture supernatant was centrifuged and discarded, and the bacteria were resuspended in a culture solution (containing ampicillin and kanamycin) four times the initial volume of the bacterial solution, and shaken overnight at 30°C and 250 rpm. On the second day, the phages were precipitated with PEG, collected, titrated, packaged, and stored. In this way, a display-type antibody phage library was obtained.

[0262] Example 5 Quality analysis of component bacterial libraries The quality of the component bacterial libraries prepared in Example 4.5 was analyzed, and the results are shown in Table 5.

[0263] TIFF0007671502000009.tif77170

[0264] When constructing the display bacterial library, the ratio of the light chain component bacterial library (KLC) to the light chain component bacterial library (LLC) is 2:1. From the above quality results, it can be estimated that the effective cloning rate of the display bacterial library is 82%. In addition, the library capacity obtained by randomly combining the above light chain component bacterial library with the heavy chain component bacterial library is theoretically up to 10 18 There was a possibility that it would become like this.

[0265] Example 6 Quality analysis of the display bacterial library 25 TG1 competent bacteria were transformed with 16 μg of the isolated and purified ligation product for display obtained in Example 4.8, and the bacteria were amplified and cultured, and then centrifuged to harvest the bacteria, resulting in a total of 2.4*10 12The bacteria were obtained, packaged, and stored (i.e., the display bacterial library prepared in Example 4.8 was obtained). The display bacterial library had a library volume of 4*10 10 , the background cloning rate was 3%, and the transformation efficiency of ligation product per μg was 2.5*10 9 It became.

[0266] The quality of the display bacterial library was analyzed in two ways.

[0267] First method: 90 bacterial colonies were randomly selected and sequenced. As a result, 56 colonies had the correct reading frame and no repetitive sequences, and the cloning rate of the correct reading frame was 62.2%.

[0268] Method 2: Anti-human Fab antibody was spread on the plate to detect the Fab expression of the above 90 clones by ELISA, resulting in the readings of the two negative controls being 0.07 and 0.082, respectively. A total of 71 clones with readings greater than 0.1 were identified as Fab expressing, with a positive rate of 79%.

[0269] Of the 34 clones with sequence errors, 18 expressed Fab when analyzed, accounting for 20% of the 90 clones. If the clones with correct sequencing were added to the clones with errors but expression (56 + 18), the effective cloning rate was 82.2% (74 / 90), which is consistent with the results estimated in Example 5.

[0270] Example 7 Quality analysis of the displayed antibody phage library The display antibody phage library in Example 4.9 was precipitated with PEG, centrifuged and resuspended in 280 ml of PBS, mixed uniformly with 60 ml of glycerin, packaged, and frozen. The frozen and stored display antibody phage library was taken and subjected to titer analysis, with the result that the titer of the phage library was 2x10 13 / ml, and the phage library contains a total of 6.8 x 10 15 This indicates that 100 μl contains 50 times the library volume of phages.

[0271] To analyze whether antigen-specific antibodies could be screened from the constructed phage library, three secreted cytokines (IL6, IL17A / F, GMCSF) and three cell membrane proteins (IL6R, EGFR, Siglec3) were selected and each antigen was screened with 100 μl of the above phage library.

[0272] Antigen-specific Fab was screened by liquid-phase screening method using magnetic beads adsorbed with biotinylated antigen-binding avidin. The six types of biotin-labeled antigens were purchased from AcroBiosystems (Cat# IL6-H8218, ILF-H82W1, GMF-H8214, CD6-H82E8, EGR-H82E3 and CD3-H82E7), and avidin-labeled magnetic beads were purchased from Thermo (Cat# 11206D). The antigen concentrations in the three liquid-phase screenings were 5 μg / ml, 3 μg / ml and 1 μg / ml, respectively. In the first screening, the phages were eluted and collected, and after amplification, they were used for the second screening. In the second screening, the phages were eluted and collected, and directly used for the third screening without amplification.

[0273] For the third round of screening, phages were eluted, harvested, infected with TG1 bacteria, plated on ampicillin-containing petri dishes, and incubated overnight at 37°C. The next day, 96 single clones were picked from each antigen-specific petri dish and cultured at OD 600 The cultures were amplified to a β-actin ratio of 0.6 (Petri dish medium as above, containing 2YT, 100 μg / ml ampicillin, and 0.2% glucose) and induced overnight with IPTG (final concentration 1 mM). On day 3, the cultures were analyzed for antigen-specific Fab by ELISA, and the results are shown in Table 6.

[0274] TIFF0007671502000010.tif65170

[0275] In Table 6, clones with ELISA readings two times greater than the lowest ELISA reading are counted as positive clones.

[0276] The results in Table 6 show that specific Fabs against IL-6, IL6R, IL17-FR, GMCSF, EGFR and Siglec3 could be screened and obtained from the above phage antibody library, and the percentage of positive clones was approximately 25-87%.

[0277] From the antigen-specific positive clones in each group, 12 clones with the highest ELISA readings were selected for sequencing analysis, and the amino acid sequences of the 12 clones in each group were aligned and analyzed. The results are shown in Table 7. The results in Table 7 show that each group has multiple unique amino acid sequences.

[0278] TIFF0007671502000011.tif23170

[0279] The above detailed description is provided for the purpose of illustration or example, but is not intended to limit the scope of the appended claims. Various modifications to the embodiments described herein are obvious to those skilled in the art, and fall within the scope of the appended claims and equivalent embodiments.

Claims

1. 1. A method for producing a phage library displaying antibodies or antibody fragments, comprising: 1) providing a first polynucleotide comprising an LC having a nucleic acid sequence encoding a light chain or a fragment of a light chain of the antibody or antibody fragment, a second polynucleotide comprising a linker, and a third polynucleotide comprising an HC having a nucleic acid sequence encoding a heavy chain or a fragment of a heavy chain of the antibody or antibody fragment; 2) obtaining a light chain component bacterial library by introducing the first polynucleotide into a first bacterium, obtaining a linker component bacterial library by introducing the second polynucleotide into a second bacterium, and obtaining a heavy chain component bacterial library by introducing the third polynucleotide into a third bacterium; 3) obtaining a light chain component plasmid comprising the LC from the light chain component bacterial library, obtaining a linker component plasmid comprising the linker from the linker component bacteria, and obtaining a heavy chain component plasmid comprising the HC from the heavy chain component bacterial library; 4) obtaining the LC released by the light chain component plasmid, obtaining the linker released by the linker component plasmid, and obtaining the HC released by the heavy chain component plasmid; 5) providing a display vector and obtaining a display vector fragment released by the display vector; 6) forming a ligation product for display by ligating the released LC, the released linker, the released HC and the released display vector fragment; 7) introducing the ligation products for display into a fourth bacterium to obtain a bacterial display library of the antibody or antibody fragment; 8) using the display bacterial library to prepare a phage library that displays the antibody or antibody fragment; the first polynucleotide comprises, in a 5'→3' direction, the structure R1-LC-R2; the second polynucleotide comprises, in a 5'→3' direction, the structure R3-Linker-R4; the third polynucleotide comprises, in a 5'→3' direction, the structure R5-HC-R6; and the display vector comprises, in a 5'→3' direction, the structure R7-Display Vector Fragment-R8, wherein R1, R2, R3, R4, R5, R6, R7, and R8 are recognition sites for a restriction endonuclease; The end of R2 cut by the restriction endonuclease is capable of recognizing and joining with the ends cut by the restriction endonuclease of R3; and does not recognize or ligate to any of the ends cleaved by any of the restriction endonucleases R1, R4, R5, R6, R7, and R8; The end cut by the restriction endonuclease of R4 is capable of recognizing and joining with the ends cut by the restriction endonuclease R5; and does not recognize or ligate to any of the ends cleaved by any of the restriction endonucleases R1, R2, R3, R6, R7, and R8; The ends cleaved by the R6 restriction endonuclease are capable of recognizing and joining the ends cleaved by the restriction endonuclease R7; and does not recognize or ligate to any of the ends cleaved by any of the restriction endonucleases R1, R2, R3, R4, R5, and R8; and The ends cleaved by the R8 restriction endonuclease are capable of recognizing and joining with the ends cut by the restriction endonuclease of R1; and does not recognize or ligate to any of the ends cleaved by the restriction endonuclease R2, R3, R4, R5, R6, and R7; The step 2) includes enzymatically digesting the first polynucleotide with a restriction endonuclease that recognizes R1 and R2, ligating the enzymatically digested first polynucleotide to a light chain storage vector fragment to form a light chain storage ligation product, and introducing the light chain component bacterial library into the first bacterium, wherein the light chain storage vector fragment is obtained by enzymatically digesting a light chain storage vector comprising R1 and R2 with a restriction endonuclease that recognizes R1 and R2; and the step 2) includes enzymatically digesting the third polynucleotide with a restriction endonuclease that recognizes R5 and R6, ligating the enzymatically digested third polynucleotide to a heavy chain storage vector fragment to form a heavy chain storage ligation product, and introducing the heavy chain component bacterial library into the third bacterium, wherein the heavy chain storage vector fragment is obtained by enzymatically digesting a heavy chain storage vector comprising R5 and R6 with a restriction endonuclease that recognizes R5 and R6. The method.

2. Under conditions suitable for expression of an antibody or antibody fragment, the ligation product for display in 6) is capable of expressing the light chain or light chain fragment and the heavy chain or heavy chain fragment in accordance with the reading frame. The method of claim 1.

3. The first polynucleotide, the second polynucleotide and the third polynucleotide are all linear nucleic acid molecules. The method according to claim 1 or 2.

4. The linker has a nucleic acid sequence encoding the signal peptide pelB or a fragment thereof. The method according to any one of claims 1 to 3.

5. Any of R1, R2, R3, R4, R5, R6, R7 and R8 has a non-palindromic end cleaved by a restriction endonuclease. The method of claim 1.

6. Two or more of R1, R2, R3, R4, R5, R6, R7 and R8 are recognizable and cleavable by the same restriction endonuclease; The method of claim 1.

7. R1, R2, R3, R4, R5 and R8 are recognizable and cleavable by the same restriction endonuclease; The method of claim 1.

8. R6 and R7 are recognizable and cleavable by the same restriction endonuclease; The method of claim 1.

9. The antibody or fragment thereof comprises Fab, Fab', (Fab)2 and / or (Fab')2. The method of claim 8.

10. The heavy chain conservation vector contains a BsmBI recognition site, and contains one BsmBI recognition site. The method of claim 1.

11. 2) ligating the second polynucleotide to a vector fragment to form a linker-storing vector, and introducing the linker-storing vector into the second bacterium, thereby obtaining the linker component bacterium; The method according to any one of claims 1 to 10.

12. The linker-conserving vector includes R3 and R4. The method of claim 11.

13. 4) performing an enzymatic digestion of the light chain component plasmid with a restriction endonuclease that recognizes the R1 and R2 to obtain the released LC; The method according to any one of claims 1 to 12.

14. 4) performing an enzymatic digestion of the heavy chain component plasmid with a restriction endonuclease that recognizes R5 and R6 to obtain the released HC; The method according to any one of claims 1 to 13.

15. 4) performing an enzymatic digestion treatment on the linker-preserving vector using a restriction endonuclease that recognizes R3 and R4 to obtain the released linker; The method according to any one of claims 11 to 14.

16. 4) obtaining an amplification product containing the linker, the R3 and the R4 by the linker-preserving vector, and performing an enzymatic digestion treatment on the amplification product using a restriction endonuclease that recognizes the R3 and R4 to obtain the released linker; The method according to any one of claims 11 to 15.

17. 5) comprises performing an enzymatic digestion treatment on the display vector using a restriction endonuclease that recognizes R7 and R8, thereby releasing the display vector fragment; The method according to any one of claims 1 to 16.

18. The display vector is derived from the pComb3x vector. The method according to any one of claims 1 to 17.

19. When the display vector is subjected to enzymatic digestion using a restriction endonuclease that recognizes R1, R2, R3, R4, R5, and R8, three different enzyme digestion fragments are obtained. The method according to any one of claims 1 to 18.

20. The display vector is linearized when the display vector is subjected to an enzymatic digestion treatment using a restriction endonuclease that recognizes R6 and R7.

20. The method according to any one of claims 1 to 19.

21. When the display vector is subjected to enzymatic digestion using a restriction endonuclease that recognizes R1, R2, R3, R4, R5, R6, R7, and R8, four different enzyme digestion fragments are obtained. The method according to any one of claims 1 to 20.

22. 2) determining library volume and / or quality of the light chain component bacterial library, the linker component bacterial library, and / or the heavy chain component bacterial library by sampling and detecting the light chain component bacterial library, the linker component bacterial library, and / or the heavy chain component bacterial library; 22. The method according to any one of claims 1 to 21.

Images